CA2804329C

CA2804329C - Bisaryl (thio)morpholine derivatives as s1p modulators

Info

Publication number: CA2804329C
Application number: CA2804329A
Authority: CA
Inventors: Wouter I. Iwema Bakker; Raymond Bronger
Original assignee: AbbVie BV
Current assignee: AbbVie BV
Priority date: 2010-07-09
Filing date: 2011-07-08
Publication date: 2019-05-14
Anticipated expiration: 2031-07-08
Also published as: EP2590954A1; TW201206893A; ES2570744T3; US20130203745A1; JP2013531003A; US9227960B2; US20160151376A1; UY33495A; WO2012004375A1; JP5841593B2; DK2590954T3; PL2590954T3; MX338605B; MX2013000361A; US20150191457A1; US9029371B2; US9662337B2; AR082137A1; CN103080096A; CA2804329A1

Abstract

The present invention relates to bisaryl (thio)morpholine derivatives of the formula (I) wherein R1 is an aryl substitutent selected from phenyl, pyridyl, pyrimidinyl, biphenyl and naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-6C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, amino, di(1-4C)alkylamino, -SO2-(1-4C)alkyl, -CO-(1-4C)alkyl, -CO-O-(1-4C)alkyl and -NH-CO-(1-4C)alkyl, or substituted with phenoxy, benzyl, benzyloxy, phenylethyl or morpholinyl, each optionally substituted with (1-4C)alkyl, and (8-10C)bicyclic group, bicyclic heterocycle, each optionally substituted with (1-4C)alkyl optionally substituted with one or more fluoro atoms or oxo; A is selected from -CO-, -NH-, -O-, -S-, -SO- or -SO2-; ring structure B optionally contains one nitrogen atom; R2 is H, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is (1-4C)alkylene-R6 wherein the alkylene group may be substituted with (CH2)2 to form a cyclopropyl moiety or with one or more halogen atoms, or R3 is (3-6C)cycloalkylene-R5 or -CO-CH2-R6, wherein R6 is -OH, -PO3H2, -OPO3H2, -COOH, -COO(1-4C)alkyl or tetrazol-5-yl; R4 is H or (1-4C)alkyl; R5 is one or more substituents independently selected from H, (1-4C)alkyl or oxo; W is -O-, -S-, -SO- or -SO2-; or a pharmaceutically acceptable salt, a solvate or hydrate thereof, with the proviso that the derivative of formula (I) is not 2-[4-(4-chlorophenoxy)-2-chloro-phenyl]-4-morpholineethanol. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of S1P receptor mediated diseases and conditions.

Description

Title: Bisaryl (thio)morpholine derivatives as sip modulators Field of the invention This invention relates to new bisaryl (thio)morpholine derivatives having affinity to S113 receptors, a pharmaceutical composition containing said compounds, as well as the use of said compounds for the preparation of a medicament for treating, alleviating or preventing diseases and conditions in which any S113 receptor is involved or in which modulation of the endogenous S113 signaling system via any S113 receptor is involved.
Background of the invention Sphingosine-l-phosphate (S1P) is a bioactive sphingolipid that mediates a wide variety of cellular responses, such as proliferation, cytoskeletal organization and migration, adherence- and tight junction assembly, and morphogenesis. S113 can bind with members of the endothelial cell differentiation gene family (EDG receptors) of plasma membrane-localized G
protein-coupled receptors. To date, five members of this family have been identified as S113 receptors in different cell types, S1P1 (EDG-1), S1P2 (EDG-5), S1P3 (EDG-3), S1P4 (EDG-6) and S1P5 (EDG-8). S113 can produce cytoskeletal re-arrangements in many cell types to regulate immune cell trafficking, vascular homeostasis and cell communication in the central nervous system (CNS) and in peripheral organ systems.
It is known that S113 is secreted by vascular endothelium and is present in blood at concentrations of 200-900 nanomolar and is bound by albumin and other plasma proteins. This provides both a stable reservoir in extracellular fluids and efficient delivery to high-affinity cell-surface receptors. S113 binds with low nanomolar affinity to the five receptors S1P1-5. In addition, platelets also contain SW and may be locally released to cause e.g. vasoconstriction.
The receptor subtypes S1P1, S1P2 and S1P3 are widely expressed and represent dominant receptors in the cardiovascular system. Further, S1P1 is also a receptor on lymphocytes. S1P4 receptors are almost exclusively in the

2 haematopoietic and lymphoid system. S1P5 is primarily (though not exclusively) expressed in central nervous system. The expression of S1P5 appears to be restricted to oligodendrocytes in mice, the myelinating cells of the brain, while in rat and man expression at the level of astrocytes and endothelial cells was found but not on oligodendrocytes.
S113 receptor modulators are compounds which signal as (ant)agonists at one or more S113 receptors. The present invention relates to modulators of the S1P5 receptor, in particular agonists, and preferably to agonists with selectivity over S1P1 and/or S1P3 receptors, in view of unwanted cardiovascular and/or immunomodulatory effects. It has now been found that S1P5 agonists can be used in the treatment of cognitive disorders, in particular age-related cognitive decline.
Although research is ongoing to develop therapeutics that can be used to treat age related cognitive decline and dementia, this has not yet resulted in many successful candidates. Therefore, there is a need for new therapeutics with the desired properties.
Description of the invention It has now been found that bisaryl (thio)morpholine derivatives of the formula (I) R1 ¨A
R4 W _______________________________ R5 (I) wherein R1 is an aryl substitutent selected from phenyl, pyridyl, pyrimidinyl, biphenyl and naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-6C)alkyl optionally substituted with one or more fluor atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, amino, di(1-4C)alkylamino,

3 -S02-(1-4C)alkyl, -00-(1-4C)alkyl, -00-0-(1-4C)alkyl and -NH-CO-(1-4C)alkyl, or substituted with phenoxy, benzyl, benzyloxy, phenylethyl or morpholinyl, each optionally substituted with (1-4C)alkyl, and (8-10C)bicyclic group, bicyclic heterocycle, each optionally substituted with (1-4C)alkyl optionally substituted with one or more fluoro atoms or oxo;
A is selected from -CO-, -NH-, -0-, -S-, -SO- or -SO2-;
ring structure B optionally contains one nitrogen atom;
R2 is H, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is (1-4C)alkylene-R6 wherein the alkylene group may be substituted with (CH2)2 to form a cyclopropyl moiety or with one or more halogen atoms, or R3 is (3-6C)cycloalkylene-R5 or -CO-CH2-R6, wherein R6 is -OH, -P03112, -0P03112, -COOH, -000(1-4C)alkyl or tetrazol-5-y1;
R4 is H or (1-4C)alkyl;
R5 is one or more substituents independently selected from H, (1-4C)alkyl or oxo;
W is -0-, -S-, -SO- or -S02-;
or a pharmaceutically acceptable salt, a solvate or hydrate thereof, with the proviso that the derivative of formula (I) is not 2-[4-(4-chlorophenoxy)-2-chloro-pheny1]-4-morpholineethanol, display affinity for S113 receptors. In particular, compounds of the invention show selective affinity for the S1P5 receptor over the S1P1 and/or 51P3 receptor(s).
The use of the compound 244-(4-chlorophenoxy)-2-chloro-pheny1]-4-morpholineethanol as a reagent in the production of 2-(2-arylmorpholino)ethyl esters of naproxen is described in Acta Chimica Sinica, vol. 66 (No. 22), 2008, 2553-2557, Hu, Ai-Xi et al, XP009137465. No pharmacological activity of the compound is reported.

4 The compounds of the invention are modulators of the S113 receptor, in particular of the S1P5 receptor. More specifically, the compounds of the invention are S1P5 receptor agonists. The compounds of the invention are useful for treating, alleviating and preventing diseases and conditions in which (any) SW receptor(s) - in particular S1P5 ¨ is (are) involved or in which modulation of the endogenous S113 signaling system via any S113 receptor is involved. In particular, the compounds of the present invention may be used to treat, alleviate or prevent CNS (central nervous system) disorders, such as neurodegenerative disorders, in particular -but not limited to- cognitive disorders (in particular age-related cognitive decline) and related conditions, Alzheimer's disease, (vascular) dementia, Nieman's Pick disease, and cognitive deficits in schizophrenia, obsessive-compulsive behavior, major depression and autism, multiple sclerosis, pain, etc.. Preferably, the compounds of the present invention may be used to treat, alleviate or prevent cognitive disorders (in particular age-related cognitive decline) and related conditions.
In an embodiment of the invention, the compounds have formula (I) wherein R3 is selected from -(CH2)2-0H, -CH2-0001-1, -(CH2)2-COOH, -(CH2)3-COOH, -CH2-CHCH3-COOH, -CH2-C(CH3)2-COOH, -CHCH3-CH2-COOH, -CH2-CF2-COOH, -CO-CH2-COOH, -(CH2)2-P03H2, -(CH2)3-P03112, -(CH2)2-0P03H2, -(CH2)3-0P03H2, -CH2-tetrazol-5-yl, -(CH2)2-tetrazol-5-y1 and -(CH2)3-tetrazol-5-yl. Preferred R3 groups are selected from -CH2-COOH, -(CH2)2-COOH, -(CH2)3-COOH, -CH2-CHCH3-COOH, -CH2-C(CH3)2-COOH, -CHCH3-CH2-COOH, -(CH2)2-P03H2, -(C112)3-P03H2 and -(CH2)2-0P03H2 and in particular -(CH2)2-COOH and -(CH2)2-P03H2. In particular preferred R3 groups are selected from -CH2-COOH, -(CH2)2-COOH, -(CH2)3-COOH, -CH2-CHCH3-COOH, -CH2-C(CH3)2-COOH and -CHCH3-CH2-COOH. Most preferred is -(CH2)2-COOH.

5 In another embodiment of the invention, the compounds have the structure (II) R1¨A
R4 W ___________________ )R5 (II).
In preferred embodiments of the invention the ring structure B is phenylene.
5 In a further embodiment of the invention, R4 is methyl or H. Preferably, R4 is H.
In another embodiment, the compounds have formula (I) wherein R2 is H or halogen. In further embodiments, R2 is trifluoromethyl.
Further, in an embodiment of the invention, A is -CO-, -NH- or -0-.
In further embodiments of the invention, R1 is selected from pyridyl, pyrimidinyl, biphenyl, naphthyl, dihydrobenzofuranyl optionally substituted with oxo, benzdioxanyl, quinolinyl, isoquinolinyl and from phenyl optionally substituted with one or more substituents independently selected from halogen, (1-6C)alkyl, di(1-4C)alkylamino (preferably dimethylamino), -S02-(1-4C)alkyl, -00-(1-4C)alkyl, -00-0-(1-4C)alkyl, -NH-00-(1-4C)alkyl, difluoromethyl, trifluoromethyl, difluoromethoxy and trifluoromethoxy, or substituted with phenoxy, benzyl, benzyloxy, phenylethyl or morpholinyl. In preferred embodiments, R1 is selected from phenyl substituted with one, two or three halogens, phenyl substituted with one halogen and one methyl or trifluoromethyl, phenyl substituted with one or two methyl groups, phenyl substituted with one or two trifluoromethyl groups, phenyl substituted with either one methoxy, one trifluoromethoxy, one ¨CO-methyl, one -S02-methyl, one -NH-CO-methyl or one -00-0-methyl.
In preferred embodiments, W is -0- or -S-.
In embodiments of the invention, R5 is H or represents an oxo group or two methyl groups, which methyl groups are preferably attached to the same carbon atom in the (thio)morpholine moiety.

6 The term halogen refers to fluoro, chloro, bromo, or iodo. Preferred halogens are fluoro and chloro, and in particular chloro.
The term (1-6C)alkyl or (1-4C)alkyl means a branched or unbranched alkyl group having 1-6 or 1-4 carbon atoms, respectively, for example methyl, ethyl, propyl, isopropyl and butyl. A preferred alkyl group is methyl.
The term (1-4C)alkoxy means an alkoxy group having 1-4 carbon atoms, wherein the alkyl moiety is as defined above.
The term (1-4C)alkylene means a branched or unbranched alkylene group having 1-4 carbon atoms, for example methylene, -CCH3CH2-, and the like. In the definition of R3 which is (1-4C)alkylene-R6, one or more carbon atoms in the alkylene group may (amongst others) independently be substituted with (CH2)2 to form a cyclopropyl moiety, meaning to form a R3 group such as X,R6 The term (3-6C)cycloalkylene means a cyclic alkyl group having two attachment points. Preferred is 1,3-cyclobutylene, haying the structure AAN-0--vvv i The term (8-10C)bicyclic group means a fused ring system of an aromatic and a non-aromatic ring structure having together 8-10 carbon atoms, for example the indane group.
The term bicyclic heterocycle encompasses bicyclic heteroaryl groups, for example indolyl, indazolyl, isoindolyl, indolizinyl, benzimidazolyl, imidazothiazolyl, imidazopyridinyl, benzfuranyl, dihydrobenzofuranyl, benzdioxanyl, quinolinyl, isoquinolinyl, quinolizinyl, tetrahydroisoquinolinyl, and the like. Preferred bicyclic heterocycles are dihydrobenzofuranyl, benzdioxanyl, quinolinyl and isoquinolinyl.

7 With reference to substituents, the term "independently" means that the substituents may be the same or different from each other in the same molecule.
The compounds of the invention may suitably be prepared by methods available in the art, and as illustrated in the experimental section of this description.
The compounds of the present invention may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers.
Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within the ambit of this invention. The present invention is meant to comprehend all such isomeric forms of these compounds. The independent syntheses of these diastereomers or their chromatographic separations may be achieved as known in the art by appropriate modification of the methodology disclosed herein. Their absolute stereochemistry may be determined by the x-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration. If desired, racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated. The separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography.

8 Compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.
.. Isotopically-labeled compound of formula (I) or pharmaceutically acceptable salts thereof, including compounds of formula (I) isotopically-labeled to be detectable by PET or SPECT, also fall within the scope of the invention. The same applies to compounds of formula (I) labeled with [13C]-7 [14q-, [3H]-, [18F] -[1251] or other isotopically enriched atoms, suitable for receptor binding or metabolism studies.
The term "pharmaceutically acceptable salt" refers to those salts that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well-known in the art.
They can be prepared in situ when isolating and purifying the compounds of the invention, or separately by reacting them with pharmaceutically acceptable non-toxic bases or acids, including inorganic or organic bases and inorganic or organic acids.
The compounds of the invention may be administered enterally or parenterally. The exact dose and regimen of these compounds and compositions thereof will be dependent on the biological activity of the compound per se, the age, weight and sex of the patient, the needs of the individual subject to whom the medicament is administered, the degree of affliction or need and the judgment of the medical practitioner. In general, parenteral administration requires lower dosages than other methods of administration which are more dependent upon adsorption. However, the dosages for humans are preferably 0.001 ¨ 10 mg per kg body weight. In

9 general, enteral and parenteral dosages will be in the range of 0.1 to 1,000 mg per day of total active ingredients.
Mixed with pharmaceutically suitable auxiliaries, e.g. as described in the standard reference "Remington, The Science and Practice of Pharmacy" (21st edition, Lippincott Williams & Wilkins, 2005, see especially Part 5:
Pharmaceutical Manufacturing) the compounds may be compressed into solid dosage units, such as pills or tablets, or be processed into capsules or suppositories. By means of pharmaceutically suitable liquids the compounds can also be applied in the form of a solution, suspension or emulsion.
For making dosage units, e.g. tablets, the use of conventional additives such as fillers, colorants, polymeric binders and the like, is contemplated. In general, any pharmaceutically suitable additive which does not interfere with the function of the active compounds can be used.
Suitable carriers with which the compounds of the invention can be administered include for instance lactose, starch, cellulose derivatives and the like, or mixtures thereof, used in suitable amounts. Compositions for intravenous administration may for example be solutions of the compounds of the invention in sterile isotonic aqueous buffer. Where necessary, the intravenous compositions may include for instance solubilizing agents, stabilizing agents and/or a local anesthetic to ease the pain at the site of the injection.
Pharmaceutical compositions of the invention may be formulated for any route of administration and comprise at least one compound of the present invention and pharmaceutically acceptable salts thereof, with any pharmaceutically suitable ingredient, excipient, carrier, adjuvant or vehicle.
By "pharmaceutically suitable" it is meant that the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
In an embodiment of the invention, a pharmaceutical pack or kit is provided comprising one or more containers filled with one or more pharmaceutical compositions of the invention. Associated with such container(s) can be various written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals products, which notice reflects approval by the agency of 5 manufacture, use, or sale for human or veterinary administration.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or

10 equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described in this document.
The following examples are intended to further illustrate the invention in more detail.
Any novel intermediate as disclosed herein is a further embodiment of the present invention.
EXAMPLES
1. MATERIALS AND METHODS
Nuclear magnetic resonance spectra (111 NMR) were determined in the indicated solvent using a Bruker Avance-I 400 with a 9.4T magnet ('H: 400 MHz, "C: 100 MHz), equipped with a BBI inversie broadband probehead with Z-gradient and ATM, or a Bruker Avance-DRX 600"with a 14.1T magnet, equipped with a TXI inverse triple resonance cryoprobehead with Z-gradient and ATM, at 300 K, unless indicated otherwise. The spectra were determined in deuterated chloroform (CDC13) with 99.8 atom% D; or in dimethylsulfwdde-d6(DMS0- de) containing 0.03 v/v% tetramethylsilane; both obtained from

11 Aldrich Chemical shifts (8) are given in ppm downfield from tetramethylsilane.

Coupling constants J are given in Hz. Peakshapes in the NMR spectra are indicated with the symbols 'q' (quartet), 'clq' (double quartet), 't' (triplet), dt' (double triplet), 'd' (doublet), 'cid' (double doublet), 's' (singlet), `bs' (broad singlet) and 'm' (multiplet). NH and OH signals were identified after mixing the sample with a drop of D20.
Melting points were recorded on a Buchi. B-545 melting point apparatus.
All reactions involving moisture sensitive compounds or conditions were carried out under an anhydrous nitrogen atmosphere.
Reactions were monitored by using thin-layer chromatography (TLC) on silica coated plastic sheets (Merck precoated silica gel 60 F254) with the indicated eluent. Spots were visualised by UV light (254 nm) or 12.
Liquid Chromatography- Mass Spectrometry (LC-MS) Column: Waters Sunfire C18, 30 x 4.6 mm with 2.5 Dm particles. The column is therm stated in a column oven at 23 C.
Detection: UV/VIS meter with the wavelength set to 254 nm + evaporative light scattering detector operating at 70 Celsius and 1.7 bar N2 pressure.
steptotal time (min)flow (ul/min)A(%) B(%) 1 1.8 1800 0 100 2 2.5 1800 0 100 3 2.7 1800 95 5 A= 99.8% Water with 0.2% HCOOH
B= 99.8% CH3CN with 0.2% HCOOH

12 The reported retention times (Rt) are for the peak in the Total Ion Current (TIC) chromatogram which showed the mass for [M+H]+ within 0.5 amu accuracy of the calculated exact MW and had an associated peak in the Evaporative Light Scattering (ELS) chromatogram with a relative area%
(purity) of >85%.
2. GENERAL ASPECTS OF SYNTHESES
Suitable syntheses of claimed compounds and intermediates containing 2-aryl-morpholine moieties follow routes as described below; see Scheme 1.
Scheme 1 NH, Q1 .
OH OH
/ \

Br OH
Qi H

(II) (III) (IV) R5 0 ¨5R5 R4 N R4 N . R4 N
. (V) (VI) H

0 R4 ¨5R5 _,.. Rls 0 ¨5..R5 Ns _,..
R4 Ns (VII) Q2 (I) R3 Qi is a group equal to R1-A, or a group that can be converted to R1-A. Q9 is a group equal to R3, or a group that can be converted to R3. For details, see the full details given below.

13 The synthesis begins with a suitably substituted acetophenone (II). Suitably substituted acetophenones are commercially available or can be obtained from other commercially available acetophenones. For example by 0-alkylation of (un)substituted 4-hydroxyacetophenones. This 0-alkylation can be done with a suitable alkylating agent like 1-bromooctane or benzyl bromide, in solvents such as dimethylsulfoxide (DMSO), acetone, or acetonitrile, in the presence of a base like potassium hydroxide or potassium carbonate, at temperatures between 0 C and 60 C.
The suitably substituted acetophenone (II) is brominated to afford 2'-bromo-acetophenones (III). Bromination can be done with copper(II) bromide in a suitable solvent like ethyl acetate with heating under reflux; via reaction of the corresponding silyl enol ether, prepared with DIPEA and TMSOTf, at 0 C, with NBS in a solvent like dichloromethane, at room temperature; or with tetra-N-butylammonium tribromide, in a solvent like methanol, at room temperature.
Reaction of the 2'-bromoacetophenones with benzyl amine, in a solvent like ethanol and chloroform, at temperatures between 0 C and room temperature, afforded aminoketones (R4 = H) which where directly reduced with a reducing agent like sodium borohydride in a solvent like ethanol and chloroform, at temperatures between 0 C and room temperature, to afford amino alcohols (IV, R4 = H). Alternatively, 2'-bromoacetophenones (III) can be reduced with a suitable reducing agent like NaBH4, in a solvent such as 1,4-dioxane, at room temperature, followed by treatment with a base, such as KOH, in a mixture of water and a suitable solvent, such as Et20, to afford 2-aryloxiranes, which on treatment with benzyl amine at a temperature of 80 C, afford amino alcohols (IV, R4 = H). Another method for the synthesis of aminoalcohols (IV, R4 = Me) is by the reaction of a suitably substituted acetophenone with trimethylsilyl cyanide in the presence of a lewis acid, like zinc iodide, at room temperature, in the neat. Followed by reduction of the intermediate cyanohydrin with a

14 reducing agent, like lithium aluminum hydride, in a solvent like tetrahydrofuran, and subsequent imine formation with benzaldehyde in the presence of an acidic catalyst, like p-toluenesulfonic acid, in a solvent such as toluene, and finally reduction of the intermediate imine with sodium borohydride, in a solvent like methanol, at temperatures between -15 C and room temperature.
The amino alcohols (IV) can be reacted with an activated chloroacetic acid or bromoacetic acid in a solvent such as dichloromethane with a base such as triethylamine, and subsequently cyclized in a solvent, such as 2-propanol or 2-methyl-2-butanol, with a base, such as potassium hydroxide or potassium tert-butoxide, to afford morpholin-3-ones. Those morpholin-3-ones can then be reduced with a reducing agent, such as borane or lithium aluminum hydride, in a solvent such as tetrahydrofuran, at temperatures between 0 C and room temperature, to afford the N-benzyl morpholines (V). Some of the N-benzyl morpholines (V) can be converted to other N-benzyl morpholines (V), see Scheme 2.
Scheme 2 R1, AL,R4 0 R1, AL
-4- Br -1. = S

(V-NHAr) (V-Br) (V-S02Ar) µ0 R4 0 ¨/ R1 R2 0 ¨) H
(V-0Ar) O R4 0 (V-CHO HAr) (V-COAr) For example V-Br can be coupled with a suitable aniline, under palladium catalysis in the presence of a base, like NaOtBu, in a solvent like toluene at temperatures around 100 C, to afford diarylamines V-NHAr. Compound V-Br can also be coupled with a suitable phenol, under copper(I) catalysis in the presence of a base, like cesium carbonate or sodium hydride, in a solvent such as toluene at temperatures around 110 C, to afford diarylethers V-0Ar.
Furthermore compounds V-Br can be reacted with n-butyl lithium is a solvent such as THF, to afford the corresponding lithium-compounds after bromine-5 lithium exchange. Those lithium compounds can then be reacted with a suitable eectrophile, such as a suitable benzaldehyde, a suitable benzenesulfonyl fluoride, or a suitable acylating reagent, to afford diarylmethanols (V-CHOHAr), diarylsulfones (V-S02Ar), or diarylketones (V-COAr). The diarylketones can also be obtained by oxidation of the 10 diarylmethanols, with oxalyl chloride, DMSO and Et3N in a solventr such as CH2C12 at a temperature of -78 C (Swern-oxidation) (Scheme 2).
Removal of the N-benzyl group in the N-benzyl morpholines (V), can be done by reaction with ACE-C1 in a solvent such as 1,2-dichloroethane, followed by reaction of the intermediate carbamate with methanol, or alternatively, by

15 hydrogenation in a solvent such as ethanol and a catalyst like palladium hydroxide to afford compounds VI. If compounds V contain a benzyloxy group (Q1 = Bn0), the benzyl-group is removed as well during the latter hydrogenation to afford compounds (VI-OH) (Scheme 1).
Morphohnes (VI) can be reacted with an (meth)acrylic acid ester, in a so called Michael-addition, in a solvent such as acetonitrile, methanol, or N,N-dimethyl-formamide, at temperatures between room temperature and 85 C, and eventually with the addition of some base like triethylamine or 1,8-diazabicyclo[5.4.0]undec-7-ene, to afford morpholin-4-yl-propionic acid esters (VIIa, Q2 = CH2CH2COOR') (Scheme 3). In case those morpholin-4-yl-propionic acid esters (VIIa, Q2 = CH2CH2COOR') contain a phenolic group (VIIa-OH), those compounds can be coupled with a suitable arylbromide, under copper(I) catalysis in the presence of a base, like cesium carbonate or sodium hydride, in a solvent such as toluene at temperatures around 140 C, in a sealed vial, to afford diarylethers VIIa-OAr.

16 Scheme 3 (VI-OH) HO =
R5 Arso 0-5R5 Ars 4p (VI-OAr) (VIIa-OH) )¨(:)=E (VIla-OAr) Compounds VIIa-OAr in which Ar = 2,6-dichlorophenyl can be obtained from VIIa-OH by reaction with 2,6-dichlorofluorobenzene and K2CO3 in a solvent such as DMF, at temperatures around 100 C.
Compounds of type VII can be converted into the final compounds I by basic or acidic hydrolysis of the ester, depending on the nature of group E. As an example, tert-butyl esters (E = C(CH3)3) can be treated with an acid, such as trifluoroacetic acid or hydrogen chloride, in a solvent such as CH2C12 or 1,4-dioxane, at room temperature.
Compounds wherein W is -S-, -SO- or -SO2- may be prepared as described below and shown in scheme 4.

17 Scheme 4 R2 R2 s ¨,- Q, Qi N N
Br 0 H H
(VIII) (IX) . S¨ _,..
-1=== R1s 40 W¨\
A
0, Pi Ns -11. Ns (X) Q2 (I, W = S, SO) R3 e \ 'S
S¨ i ¨1... Q1 . ¨\ i N N N
(IX) H o'> )-0 (XI) \ 0 ?\

R2 0, ii R2 00 R2 .,0 Ozzsi '¨\ R1 -- Q1 * S ) ¨3. Qi . ' ¨ 'A 11 N Ns Ns (XII) H (Xi ii) Q2 (I, W =
SO2) R3 Q1 is a group equal to R1-A, or a group that can be converted to R1-A. Q2 is a group equal to R3, or a group that can be converted to R3. For details, see the full details given below.
The synthesis begins with a suitably substituted bromo-phenyl-acetic acid ester. Suitably substituted bromo-phenyl-acetic acid esters are commercially available or can be obtained according to methods known in the literature. The bromo-phenyl-acetic acid ester is reacted with 2-aminoethanethiol, in the presence of a base, such as potassium carbonate, in a solvent such as ethanol, at room temperature, to obtain 2-aryl-thiomorpholin-3-ones (VIII). Those thiomorpholin-3-ones can then be reduced with a reducing agent such as borane in a solvent such as tetrahydrofuran, at temperatures between 0 C and room temperature, to afford the 2-aryl-thiomorpholines (IX). Thiomorpholines (IX) can be reacted with an (meth)acrylic acid ester, in a so called Michael-

18 addition, in a solvent such as acetonitrile, methanol, or N,N-dimethyl-formamide, at temperatures between room temperature and 85 C, and eventually with the addition of some base like triethylamine or 1,8-diazabicyclo[5.4.0]undec-7-ene, to afford morpholin-4-yl-propionic acid esters (X, Q2 = CH2CH2COOR'). In case those thiomorpholin-4-yl-propionic acid esters (X, Q2 = CH2CH2COOR') are substituted with bromine (X, Q1 = Br), the bromine can be replaced by iodine (X, Q1 = I) in a reaction with sodium iodide, catalysed by copper(I) iodide, in the presence of N,N-dimethylethylenediamine, in a solvent such as 1,4-dioxane, at temperatures around 130 C, in a closed vessel. Subsequently, the iodine (X, Q1 = I), can be substituted by a suitable phenol, in the presence of a base such as potassium phosphate tribasic, and catalyzed by copper(I) iodide and picolinic acid, in a solvent such as dimethylsulfoxide, at a temperature around 90 C, to obtain compounds in which Q1 is equal to R1-A, and Q2 = CH2CH2COOR'. In case R' is tert-butyl, the ester can be hydrolyzed with acid, such as hydrochloric acid, in a solvent such as 1,4-dioxane, at temperatures between room temperature and 80 C, to afford compounds (I, W = S). Thiomorpholines (X, W = S, Q1 = R1-A, Q2 =
CH2CH2COOR'), can be oxidized with an oxidizing reagent such as potassium peroxymonosulfate (Oxone), in a solvent such as methanol/water, at temperatures between 0 C and room temperature to afford the thiomorpholine 1-oxides (X, W = SO, Q1 = R1-A, Q2 = CH2CH2COOR'). In case R' is tert-butyl acid hydrolysis as described for the thiomorpholines affords compounds (I, W =

SO).
Thiomorpholines (IX) can be protected at the nitrogen with a suitable protecting group (P.G.M. Wuts, T.W. Greene Protective groups in organic synthesis, 4th ed., John Wiley & Sons, 2006), such as tert-butyloxycarbonyl (BOC), by reaction with di-tert-butyl dicarbonate in a solvent such as acetonitrile at room temperature. Subsequently, the thiomorpholines can be oxidized with an oxidizing reagent such as 3-chloroperoxybenzoic acid, in a solvent such as dchloromethane, at temperatures between 0 C and room

19 temperature, to obtain thiomorpholine 1,1-dioxides (XI). After which the tert-butyloxycarbonyl (BOC) group can be removed by the treatment with an acid, such as hydrogen chloride, in a solvent such as ethanol, at temperatures between room temperature and 60 C, to afford modified thiomorpholine 1,1-dioxides (XII). Thiomorpholine 1,1-dioxides can then be reacted in a so called Michael reaction as described above for the thiomorpholines, to obtain compounds XIII (Q2 = CH2CH2COOR'). In case compounds XIII are substituted with iodine (Q1 = I), they can be substituted by a suitable phenol, in the presence of a base such as potassium phosphate tribasic, and catalyzed by a copper salt, such as copper(I) iodiode, and a suitable ligand, such as picolinic acid, in a solvent such as dimethylsulfoxide, at a temperature around 90 C, to obtain compounds XIII (W = S02, Q1 = R1-A, Q2 = CH2CH2COOR').
In case R' is tert-butyl acid hydrolysis as described for the thiomorpholines affords compounds (I, W = SO2).
Abbreviations ACE-C1 1-Chloroethyl chloroformate BINAP 2,2'-bis(diphenylphosphino)-1,1'-binaphthalene BH3=THF Borane tetrahydrofuran complex n-BuLi n-Butyllithium n-Bu4NBr Tetrabutylammonium bromide CD3OD Methanol-d4 CHC13 Chloroform CD C13 Chloroform- d CH2C12 Dichloromethane CH3CN Acetonitrile Cs2CO3 Cesium carbonate CuBr Copper(I) bromide CuI Copper(I) iodide DIPEA NN-Diisopropylethylamine DMF N,N- dimethylformamide DMSO Dimethyl sulfoxide Et3N Triethylamine Et90 Diethyl ether 5 Et0H Ethanol Et0Ac Ethyl acetate HC1 Hydrogen chloride K2CO3 Potassium carbonate KF Potassium fluoride 10 KOH Potassium hydroxide KOtBu Potassium tert-butoxide K3PO4 Potassium phosphate tribasic LiA1114 Lithium aluminum hydride LiHMDS Lithium bis(trimethylsilyl)amide 15 Mel Methyl iodide MeMgBr Methylmagnesium bromide Me0H Methanol min. minutes MgSO4 Magnesium sulfate

20 NaBH4 Sodium borohydride Nail Sodium hydride NaHCO3 Sodium bicarbonate NaI Sodium Iodide NaN3 Sodium azide NaOH Sodium hydroxide NaOtBu Sodium tert-butoxide Na2SO4 Sodium sulfate NBS N-Bromosuccinimide NH4C1 Ammonium chloride NH4OH Ammonium hydroxide

21 Pd2(dba) 3 Tris(dibenzylideneacetone)dipalladium(0) iPr20 Diisopropyl ether RT Room Temperature SiO2 Silica gel TFA Trifluoroacetic acid THF Tetrahydrofuran TMSOTf Trimethylsilyl trifluoromethanesulfonate Xantphos 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene ZrC14 Zirconium tetrachloride 3. SYNTHESES OF INTERMEDIATES
F F F

O.
'S, Methanesulfonic acid 4-acetyl-3-trifluoromethyl-phenyl ester : To a solution of 1-(4-hydroxy-2-trifluoromethyl-pheny1)-ethanone (29.74 g; 145.7 mmol) in CH2C12 (300 mL) and THF (120 mL) was added Et3N (24.4 mL; 174.8 mmol), at 0 C. To the resulting mixture was added dropwise a solution of methanesulfonyl chloride (12. 5 mL; 160.3 mmol) in CH2C12 (60 mL), at 0 C.
Subsequently the mixture was stirred overnight at RT, and poured in ice-water. The layers were separated and the organic layer was washed with 1 M
aqueous HC1 and water; dried (MgSO4), filtered and concentrated in vacuo to afford methanesulfonic acid 4-acetyl-3-trifluoromethyl-phenyl ester (40.47 g), which was used as such.
The following compounds were prepared in an analogues manner:
Methanesulfonic acid 4-acetyl-2-chloro-phenyl ester Methanesulfonic acid 4-acetyl-3-fluoro-phenyl ester

22 Br = 0 1-(4-Benzyloxy-phenyl)-2-bromo-ethanone: To a solution of 1-(4-(benzyloxy)-pheny1)-ethanone (49.12 g; 217.1 mmol) in CH2C12 (750 mL) was added drop wise DIPEA (45.37 mL; 260.5 mmol) and TMSOTf (45.18 mL; 249.6 mmol), both at 0 C. The resulting solution was maintained at 0 C for 1 h, and then NBS (42.50 g; 238.8 mmol) was added in four portions. The resulting mixture was allowed to warm to RT and stirred 1 hour. Subsequently, the mixture was concentrated in vacuo and the residue was treated with Et0Ac and washed twice with water, and brine. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by column chormatography (5i02, Et20) and crystallization from iPr20 to afford 1-(4-benzyloxy-pheny1)-2-bromo-ethanone.
The following compound was obtained according to a similar manner:
Methanesulfonic acid 4-(2-bromo-acetyl)-3-trifluoromethyl-phenyl ester Methanesulfonic acid 4-(2-bromo-acetyl)-2-chloro-phenyl ester Methanesulfonic acid 4-(2-bromo-acetyl)-3-fluoro-phenyl ester 1-(3-Benzyloxy-phenyl)-2-bromo-ethanone -N

2-Azido-1-(4-benzyloxy-phenyl)-ethanone: To a mixture of 1-(4-benzyloxy-pheny1)-2-bromo-ethanone (28.55 g; 93.6 mmol) in CH2C12 (300 mL) and water (30 mL) was added nBu4NBr (1.51 g; 4.7 mmol) and NaN3 (6.69 g; 102.9 mmol) in one portion. After 4h at RT, the layers were separated. The organic layer

23 was washed water, dried (Na2SO4), filtered and concentrated in vacuo to afford 2-azido-1-(4-benzyloxy-pheny1)-ethanone (23.64 g) FFF

S, Methanesulfonic acid 4-oxirany1-3-trifluoromethyl-phenyl ester : To a solution of methanesulfonic acid 4-(2-bromo-acety1)-3-trifluoromethyl-phenyl ester (33.95 g; 89.3 mmol) in 1,4-dioxane (150 mL) was added dropwise a solution of NaBH4 (2.37 g; 62.5 mmol) in water (47 mL). The resulting mixture was stirred at RT for 2.5 hours, subsequently, quenched with 0.5M aqueous HC1 (125 mL), and extracted with Et0Ac. The combined organic layers were washed with water, dried (MgSO4), filtered and concentrated in vacuo. The residue was dissolved in Et20 (500 mL) and treated with a solution of KOH
(4.19 g; 74.7 mmol) in water (100 mL). The resulting mixture was heated under reflux for 4 hours. After cooling to RT, the volatiles were removed in vacuo and the residue was partitioned between Et0Ac and water. The organic layer was washed with water, dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by column chromatography (CH2C12) to afford methanesulfonic acid 4-oxirany1-3-trifluoromethyl-phenyl ester (23.54 g).
The following compounds were prepared in an analogues manner:
Methanesulfonic acid 4-oxirany1-3-fluoro-phenyl ester Methanesulfonic acid 4-oxirany1-2-chloro-phenyl ester OH
H
Br 2-Benzylamino-1-(4-bromo-phenyl)-ethanol: To a cooled (0 C) suspension of 2-bromo-1-(4-bromophenybethanone (40.24 g; 0.14 mol) in Et0H (500 mL)

24 and CHC13 (100 mL) was added benzylamine (63 mL; 0.58 mol). After 30 minutes the ice-bath was removed and the mixture stirred for another 2 hours at RT. Subsequently the reaction mixture was cooled again to 0 C and NaBH4 (6.26 g; 165.5 mmol) was added in small portions. The resulting mixture was stirred at 0 C for 1 hour and thereafter another 4 hours at RT. The reaction mixture was quenched with 1M aqueous HC1 (750 mL) at 0 C and stirred at RT for 1 hour. The reaction mixture was concentrated in vacuo and the residue was partitioned between Et0Ac and 1M aqueous NaOH. The organic layer was dried (Na2SO4), filtered, concentrated in vacuo. The residue was crystallized from tert-butyl methyl ether/heptanes to afford 2-benzylamino-1-(4-bromo-pheny1)-ethanol (18.8 g).
The following compound was obtained according to a similar manner:
2-Benzylamino-1-(4-benzyloxy-phenyl)-ethanol 2-Benzylamino-1-(3-benzyloxy-phenyl)-ethanol F F F
OH
H

Methanesulfonic acid 4-(2-benzylamino-1-hydroxy-ethyl)-3-trifluoromethyl-phenyl ester : Methanesulfonic acid 4-oxirany1-3-trifluoromethyl-phenyl ester (23.54 g; 79.2 mmol) was dissolved in benzylamine (26 mL). The resulting mixture was stirrred at 80 C for 4h. After cooling to RT, Et20 was added and the mixture cooled to 0 C. The formed precipitate was collected by filtration, washed with Et20, and dried under vacuum, at 40 C, to afford methanesulfonic acid 4-(2-benzylamino-1-hydroxy-ethyl)-3-trifluoromethyl-phenyl ester as a white solid (26.87 g) which was used as such.

The following compounds were prepared in a similar manner:
Methanesulfonic acid 4-(2-benzylamino-1-hydroxy-ethyl)-3-fluoro-phenyl ester Methanesulfonic acid 4-(2-benzylamino-1-hydroxy-ethyl)-2-chloro-5 phenyl ester OH

2-Amino-1-(4-benzyloxy-phenyl)-ethanol: To a suspension of LiA1H4 (8.18 g; 215.6 mmol) in THF (100 mL), was added dropwise a solution of 2-azido-1-10 (4-benzyloxy-phenyl)-ethanone (23.05 g; 86.2 mmol) in THF (200 mL), at 0 C.
The mixture was stirred at 0 C for 20 min. and subsequently 2 hours at RT.
Thereafter, water (50 mL), and 2M aqueous NaOH-solution (150 mL) were added consecutively. The formed precipitate was removed by filtration over kieselguhr, and washed with Me0H. The filtrate was concentrated in vacuo 15 and the remaining aqueous layer was extracted with CH2C12. The combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo to afford 2-amino-1-(4-benzyloxy-phenyl)-ethanol (20.10 g).
OH

20 1-Amino-2-(4-benzyloxy-phenyl)-propan-2-ol: A mixture of 1-(4-benzyloxy-phenyl)-ethanone (18.50 g; 81.8 mmol), zinc iodide (0.52 g; 1.6 mmol), and trimethylsilyl cyanide (33.8 mL; 269.8 mmol) was stirred overnight at RT.
Subsequently, the excess trimethylsilyl cyanide was removed in vacuo, and the residue dissolved in THF (100 mL). The resulting solution was added, dropwise, to a mixture of LiA1H4 (12.7 g; 335.2 mmol) in THF (200 mL). The resulting mixture was heated under reflux for 2 h. Next, the mixture was cooled to 0 C and treated successively with water (13 mL), 2M aqueous NaOH
(26 mL), and water (13 mL). Thereafter the mixture was heated under reflux for 15 minutes, cooled again to RT, filtered over Kieselguhr, and concentrated in vacuo. The residue was purified by column chromatography (SiO2, Me0H) to afford 1-Amino-2-(4-benzyloxy-phenyl)-propan-2-ol (18.15 g).
OH
NH SI

1-Benzylamino-2-(4-benzyloxy-phenyl)-propan-2-ol: A mixture of 1-amino-2-(4-benzyloxy-phenyl)-propan-2-ol (1.26 g; 4.9 mmol), benzaldehyde (0.55 mL; 5.4 mmol), and p-toluenesulfonic acid (0.04 g; 0.24 mmol) in toluene (30 mL) was heated under reflux in a Dean-Stark apparatus, overnight.
Subsequently, the mixture was cooled to RT and the solvent was removed in vacuo. The residue was suspended in Me0H (30 mL), cooled to -15 C, and treated with NaBH4 (0.74 g; 19.6 mmol), portionwise. After the addition was complete the mixture was warmed to RT and stirred for one hour.
Subsequently, the Me0H was removed in vacuo. The residue was partitioned between Et20 and 5% aqueous NaHCO3. The organic layer was dried (Na2SO4), filtered, and concentrated in vacuo. The residue was purified by column chromatography (5i02, Et20: hexanes 2:1) to give 1-benzylamino-2-(4-benzyloxy-phenyl)-propan-2-ol (1.07 g).
Br 4-Benzy1-6-(4-bromo-phenyl)-morpholin-3-one: To a solution of 2-benzylamino-1-(4-bromo-pheny1)-ethanol (18.95 g; 62 mmol) and Et3N (9.6 mL;
68 mmol) in CH2C12 (500 mL) was added dropwise a solution of chloroacetyl chloride (5.4 mL; 68 mmol) in C112C12 (20 mL), at 0 C. After 1 hour at 0 C the reaction mixture was quenched with 1M aqueous HC1 (200 mL). The layers were separated and the organic layer washed with a 5% aqueous NaHCO3 solution, dried (Na9SO4) and concentrated in vacuo. The residue was dissolved in 2-propanol (200 mL) and KOH (4.2 g; 75 mmol) was added. The resulting mixture was stirred at RT for 3 hours and subsequently concentrated in vacuo.
The crude product was partitioned between CH2C12 and 1M aqueous HC1. The layers were separated and the organic layer was washed with saturated aqueous NaHCO3 solution, dried (Na2SO4) and evaporated in vacuo to afford 4-benzy1-6-(4-bromo-pheny1)-morpholin-3-one (22.30 g) which was used as such in the next step.
The following compound was obtained according to a similar manner:
4-Benzy1-6-(4-benzyloxy-phenyl)-morpholin-3-one 4-Benzy1-6-(3-benzyloxy-phenyl)-morpholin-3-one 4-Benzy1-6-(4-benzyloxy-phenyl)-6-methyl-morpholin-3-one The following compounds were obtained according to a similar manner from methanesulfonic acid phenyl esters using 2.5 equivalents of KOH instead of 1.25 equivalents:
4-Benzy1-6-(4-hydroxy-2-trifluoromethyl-phenyl)-morpholin-3-one 4-Benzy1-6-(2-fluoro-4-hydroxy-phenyl)-morpholin-3-one 4-Benzy1-6-(3-chloro-4-hydroxy-phenyl)-morpholin-3-one CI
OHL`r 1.1 NH
o N12-(4-Benzyloxy-pheny1)-2-hydroxy-ethyl]-2-chloro-acetamide: To a mixture of 2-amino-1-(4-benzyloxy-pheny1)-ethanol (20.10 g; 82.6 mmol), Et3N
(13.82 mL; 99.1 mmol), CH2C12 (200 mL) and Me0H (20 mL) was added dropwise chloroacetyl chloride (7.24 mL; 90.9 mmol) at -10 C. The resulting mixture was allowed to warm to RT and stirred overnight, and subsequently concentrated in vacuo. The residue was purified by flash chromatography (SiO2, Et0Ac) to afford N- [2-(4-benzyloxy-pheny1)-2-hydroxy-ethyl]-2-chloro-acetamide (17.45 g).

NH

6-(4-Benzyloxy-phenyl)-morpholin-3-one: To a solution of KOtBu (6.68 g;
59.5 mmol) in 2-methyl-2-butanol (100 mL) was added dropwise a solution of N42-(4-benzyloxy-pheny1)-2-hydroxy-ethyl]-2-chloro-acetamide (17.30 g; 54.1 mmol) in THF (100 mL). The resulting mixture was stirred for 1 hour at RT
and then concentrated in vacuo. The residue was dissolved in CH2C12 and treated with a 1M aqueous solution of HC1, at 0 C. The layers were separated and the aqueous layer extracted with C112C12. The combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo to afford 6-(4-benzyloxy-phenyl)-morpholin-3-one (14.10 g).

Xr oo 1411) 4-Benzy1-6-(4-benzyloxy-phenyl)-2,2-dimethyl-morpholin-3-one and 4-Benzy1-6-(4-benzyloxy-pheny1)-2-methyl-morpholin-3-one: To a solution of 4-benzy1-6-(4-benzyloxy-phenyl)-morpholin-3-one (6.90 g; 18.5 mmol) in THF (100 mL) was added dropwise a solution of LiHMDS in THF (18.5 mL;
1.00 mo1/1; 18.5 mmol), at -78 C. The resulting mixture was stirred at -78 C
for minutes, subsequently, Mel (1.15 mL; 18.5 mmol) was added, and the resulting mixture stirred for 1 hour at -78 C. The sequence of addition of LiHMDS and Mel, was repeated three times. After the last addition of Mel the 10 mixture was allowed to warm to RT and stirred overnight. Then an 5%
aqueous NaHCO3 solution was added en the mixture extracted with Et0Ac.
The combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by column chromatography (SiO2, Et20/hexanes 1:1) to afford two compounds. The least polar compound was 4-15 benzy1-6-(4-benzyloxy-pheny1)-2,2-dimethyl-morpholin-3-one (1.90 g), and the most polar compound was 4-benzy1-6-(4-benzyloxy-pheny1)-2-methyl-morpholin-3-one (3.81 g).
NH

Br 2-(4-Bromo-phenyl)-thiomorpholin-3-one: To a solution of 2-aminoethanethiol hydrochloride (6.93 g; 61 mmol) in Et0H (400 mL) was added K2CO3 (16.86 g; 122 mmol), at RT, followed after 15 minutes by bromo-(4-bromo-pheny1)-acetic acid ethyl ester (12 mL; 61 mmol). The resulting mixture was stirred at RT for two days, subsequently, water was added and the resulting mixture was extracted with Et0Ac. The combined organic layers were dried (MgSO4), filtered, and concentrated in vacuo. The residue was recrystallized from Et0H to afford 2-(4-bromo-pheny1)-thiomorpholin-3-one (12.8 g).

Br N

4-Benzy1-6-(4-bromo-phenyl)-morpholine: To a solution of 4-benzy1-6-(4-bromo-pheny1)-morpholin-3-one (21.3 g; 62 mmol) in THF (350 mL) was added BH3-THF in THF (1M, 155 mL; 155 mmol) dropwise, at 0 C. After 1 hour the 10 mixture was allowed to warm to RT and stirred for another 2 hours. To the reaction mixture was added Me0H (300 mL), at 0 C, the resulting mixture was stirred at RT for 3 days, and subsequently concentrated in vacuo. The residue was partitioned between Et0Ac and 1 M aqueous NaOH-solution. The organic layer was dried (Na2SO4), filtered, and concentrated in vacuo to afford 15 4-benzy1-2-(4-bromo-phenyl)-morpholine (20.1 g), which was used as such in the next step.
The following compound was obtained according to a similar manner:
4-Benzy1-2-(4-benzyloxy-phenyl)-morpholine 20 4-Benzy1-2-(3-benzyloxy-phenyl)-morpholine 4-Benzy1-2-(4-benzyloxy-phenyl)-2-methyl-morpholine 4-Benzy1-6-(4-benzyloxy-phenyl)-2,2-dimethyl-morpholine F F

N
HO

4-(4-Benzyl-morpholin-2-y1)-3-trifluoromethyl-phenol: To a solution of 4-benzy1-6-(4-hydroxy-2-trifluoromethyl-pheny1)-morpholin-3-one (26.18 g; 67.3 mmol) in THF (600 mL) was added dropwise BH3=THF in THF (235.4 mL; 1.00 mo1/1; 235.4 mmol), at 0 C. The resulting mixture was stirred for 1 hour at 0 C
and thereafter 18 hours at RT. Subsequently, 1M aqueous HC1 (550 mL) was added and the mixture stirred overnight at RT. The resulting mixture was partitioned between Et0Ac and 2M aqueous NaOH (350 mL), the organic layers was dried (MgSO4), filtered, and concentrated in vacuo. The residue was purified by column chromatography (SiO2, CH2C12/Me0H 98:2) to afford 4-(4-benzyl-morpholin-2-y1)-3-trifluoromethyl-phenol The following compounds were obtained according to a similar manner:
4-(4-Benzyl-morpholin-2-y1)-3-fluoro-phenol 2-(4-Bromo-phenyl)-thiomorpholine o CI
HO
4-(4-Benzyl-morpholin-2-y1)-2-ehloro-phenol: To a solution of 4-benzy1-6-(3-chloro-4-hydroxy-phenyl)-morpholin-3-one (13.05 g; 39.0 mmol) in THF (600 mL) was added portionwise L1A1114 (4.44 g; 117.04 mmol) at 0 C. The resulting mixtures was allowed to warm to RT and stirred overnight. Subsequently, the mixture was cooled to 0 C, and water (4.5 mL), a 2M aqueous NaOH-solution (9.0 mL) and water (9.0 mL) were added consecutively.Thereafter the mixture was stirred for lh. The formed precipitate was removed by filtration over kieselguhr, and washed with Et0Ac. The organic solution was concentrated in vacuo, and the residue purified by column chromatography (SiO2, CH2C12/Me0H 98:2) to afford 4-(4-benzyl-morpholin-2-y1)-2-chloro-phenol (9.10 0 _________________________________________ =0 4-Benzy1-2-(4-benzyloxy-phenyl)-5,5-dimethyl-morpholine: To a solution of 4-benzy1-6-(4-benzyloxy-phenyl)-morpholin-3-one (7.14 g; 19.1 mmol) in THF
(100 mL) was added ZrC14 (4.46 g; 19.1 mmol), at -10 C. The resulting mixture was stirred for 30 min. at -10 C, subsequently, a solution of MeMgBr in Et90 (38.2 mL; 3.00 mo1/1; 114.6 mmol) was added dropwise, keeping the temperature below 10 C. After complete addition the resulting mixture was stirred at RT for 1 hour. After cooling the mixture to 0 C a 2M aqueous NaOH
solution was added dropwise. The resulting suspension was filtered and the filtrate was extracted three times with CH9C19. The combined organic layers were dried (Na2SO4), filtered, and concentrated in vacuo. The residue was purified by column chromatography (Si02, Et20/hexanes 1:3) to afford 4-benzy1-2-(4-benzyloxy-pheny1)-5,5-dimethyl-morpholine (3.6 g).

ci CI
[4-(4-Benzyl-morpholin-2-y1)-pheny1]-(2,6-dichloro-pheny1)-amine: To a solution of BINAP (112.45 mg; 0.18 mmol) in degassed toluene (20 mL) was added 4-benzy1-2-(4-bromo-pheny1)-morpholine (1.00 g; 3.01 mmol), 2,6-dichloroaniline (0.49 g; 3.01 mmol), Pd2(dba)3 (55.12 mg; 0.06 mmol) and NaOtBu (0.29 g; 3.01 mmol). The resulting mixture was heated at 100 C for 18 h. After cooling to RT the resulting mixture was filtered over kieselguhr, rinsed with C112C12, and concentrated in vacuo. The residue was purified by column chromatography (Et20 : hexanes 1:3) to afford [4-(4-benzyl-morpholin-2-y1)-pheny1]-(2,6-dichloro-pheny1)-amine (0.73 g).
The following compound was obtained according to a similar manner:
[4-(4-Benzyl-morpholin-2-y1)-phenyl]-(2,6-dimethyl-pheny1)-amine.
FFF
011\1 4-Benzy1-244-(3-trifluoromethyl-phenoxy)-phenyThmorpholine: A
mixture of 4-benzy1-2-(4-bromo-phenyl)-morpholine (1.5 g, 4,6 mmol), 3-(trifluoromethyl)phenol (0.83 mL, 6.8 mmol), copper(I) iodide (438 mg, 2,3 mmol), 2,2,6,6-tetramethy1-3,5-heptanedione (0,48 mL, 2,3 mmol), and cesium carbonate (2,96 g, 9.1 mmol), in toluene (20 mL) was heated under reflux for 3 days. After cooling to room temperature, the mixture was partitioned between Et0Ac and water. The layers were separated. The organic layer was dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by column chromatography (Et0Ac : heptanes 5:95) to afford 4-benzy1-214-(3-trifluoromethyl-phenoxy)-pheny1]-morpholine (0.9 g). which was used as such in the next step.
The following compound was made in a similar manner:
4-Benzy1-244-(2-methyl-phenoxy)-phenyll-morpholine SOON

4-Benzy1-244-(2,6-dimethyl-phenoxy)-phenyll-morpholine: 2,6-Dimethylphenol was added portionwise to a suspension of NaH (272 mg, 60%
in oil, 6.8 mmol) in toluene (15 mL). After complete addition the mixture was heated under reflux for 15 min. and subsequently cooled to room temperature.
To the resulting mixture was added a solution of 4-benzy1-2-(4-bromo-pheny1)-morpholine (1.5 g, 4,5 mmol) in toluene (10 mL), followed by copper(I) iodide (438 mg, 2,3 mmol), 2,2,6,6-tetramethy1-3,5-heptanedione (0,48 mL, 2,3 mmol), and cesium carbonate (2,96 g, 9.1 mmol). The obtained mixture was heated under reflux for 3 days. After cooling to room temperature, the mixture was partitioned between Et0Ac and water. The layers were separated. The organic layer was dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by column chromatography (Et0Ac : heptanes 5:95) to afford 4-benzy1-214-(2,6-dimethyl-phenoxy)-phenyThmorpholine (1.2 g), which was used as such in the next step.
CI

4-Benzy1-2-[3-chloro-4-(2,6-dichloro-phenoxy)-phenyll-morpholine: A
solution of 4-(4-benzyl-morpholin-2-y1)-2-chloro-phenol (0.50 g; 1.56 mmol), 2,6-dichlorofluorobenzene (0.26 g; 1.56 mmol) and K2CO3 (0.32 g; 2.35 mmol) in DMF (10 mL) was heated at 100 C for three days. After cooling to RT, the mixture was diluted with Et0Ac and washed with water (3X). The organic layer was dried (MgSO4), filtered, and concentrated in vacuo. The residue was purified by column chromatography (SiO2, CH2C12 / Me0H 99.5:0.5) to afford 4-Benzy1-2-[3-chloro-4-(2,6-dichloro-phenoxy)-pheny1]-morpholine (0.35 g).

[4-(4-Benzyl-morpholin-2-y1)-pheny11-(3-trifluoromethyl-pheny1)-methanone: To a solution of 4-benzy1-2-(4-bromo-phenyl)-morpholine (1.89 g, 5.7 mmol) in THF (30 mL), at -78 C, was added dropwise n-butyl lithium (2.85 5 mL; 2.5 mo1/1 in hexanes; 7.1 mmol). The mixture was stirred for 20 min.
at -78 C, and subsequently N-Methoxy-N-methyl-3-trifluoromethyl-benzamide (2.66 g, 11.4 mmol) was added. The mixture was allowed to warm to RT and stirred overnight. The resulting mixture was partitioned between an aqueous saturated NH4C1 solution and Et0Ac. The layers were separated. The organic 10 layer was washed with a saturated aqueous NaHCO3-solution, dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by column chromatography (Et0Ac : heptanes 1:3) to afford [4-(4-benzyl-morpholin-2-y1)-pheny1]-(3-trifluorometh371-pheny1)-methanone (0.84 g), which was used as such in the next step.
The following compound was made in a similar manner:
[4-(4-Benzyl-morpholin-2-y1)-phenyl]-o-tolyl-methanone cc OH
[4-(4-Benzyl-morpholin-2-y1)-pheny11-(2,6-dimethyl-pheny1)-methanol:
To a solution of 4-benzy1-2-(4-bromo-phenyl)-morpholine (2.1 g, 6.3 mmol) in THF (30 mL), at -78 C, was added dropwise t-butyl lithium (7.9 mL; 1.6 mo1/1 in heptanes; 12.6 mmol). The mixture was stirred for 20 min. at -78 C, and subsequently 2,6-dimethylbenzaldehyde (1 g, 7.6 mmol) was added. The mixture was allowed to warm to RT and stirred overnight. The resulting mixture was partitioned between water and Et0Ac. The layers were separated. The organic layer was washed with water, dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by column .. chromatography (Et0Ac : heptanes 1:1) to afford [4-(4-benzyl-morpholin-2-y1)-pheny1]-(2,6-dimethyl-pheny1)-methanol (1.6 g), which was used as such in the next step.
The following compound was made in a similar manner:
[4-(4-Benzy1-morpho1in-2-y1)-pheny11-(2,6-dichloro-pheny1)-methanol çxcN 411) [4-(4-Benzyl-morpho1in-2-y1)-pheny11-(2,6-dimethyl-pheny1)-methanone: To a solution of oxalyl chloride (0.46 mL. 5,4 mmol) in CH2C12 (20 mL), was added dropwise DMSO (0.94 mL, 13.2 mmol). at -78 C.
Subsequently, a solution of [4-(4-benzyl-morpholin-2-y1)-pheny1]-(2,6-dimethyl-pheny1)-methanol (1.6 g, 4.1 mmol) in CH2C12 (30 mL) was added, dropwise, at -78 C. After the addition was complete the mixture was stirred for 30 min., at -78 C, and then Et3N (2.9 mL. 20.8 mmol) was added. After complete addition the mixture was allowed to warm to room temperature, overnight. Next, a 2M
aqueous NH4OH solution (30 mL) was added, and the mixture extracted with CH2C12. The combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo to afford [4-(4-benzyl-morpholin-2-y1)-pheny1]-(2,6-dimethyl-pheny1)-methanone (1.5 g), which was used as such in the next step.
The following compound was made in a similar manner:
[4-(4-Benzyl-morpholin-2-y1)-pheny1]-(2,6-dichloro-pheny1)-methanone 4-Benzy1-214-(2,6-dimethyl-phenylsulfany1)-phenyll-morpholine: To a solution of 4-benzy1-2-(4-bromo-pheny1)-morpholine (2.00 g; 6.02 mmol) and 2,6-dimethylthiophenol (0.88 mL; 6.62 mmol) in DMF (15 mL) was added CuBr (0.43 g; 3.01 mmol), 1,2,3,4-tetrahydro-quinolin-8-ol (0.45 g; 3.01 mmol) and Cs2CO3 (2.45 g; 7.52 mmol; 1.25 eq.). The resulting mixture was heated, in a closed vessel, at 130 C, for 2 days. After cooling to RT, water was added and the mixture extracted with Et20. The combined organic layers were washed with water, dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by column chromatography (Et20 / hexanes 1:1) to afford 4-benzy1-2-[4-(2,6-dimethyl-phenylsulfany1)-phenyl]-morpholine (1.60 g).
The following compounds were made in a similar manner:
4-Benzy1-214-(2,3-dichloro-phenylsulfany1)-phenyll-morpholine 4-Benzy1-2-(4-o-tolylsulfanyl-phenyl)-morpholine o 2-(4-Benzenesulfonyl-phenyl)-4-benzyl-morpholine: To a degassed .. mixture of 4-benzy1-6-(4-bromo-phenyl)-morpholine (0.45 g; 1.35 mmol).
sodium benzenesulfinate (0.27 g; 1.63 mmol), Cs2CO3 (0.66 g; 2.03 mmol), and tetrabutylammonium chloride (0.45 g; 1.63 mmol) in toluene (10 mL), was added Pd2dba3 (31.01 mg; 0.03 mmol) and Xantphos (39.19 mg; 0.07 mmol).
The resulting mixture was heated under reflux for 2 days. After cooling to RT, Et0Ac and a 5% aqueous NaHCO3 solution were added. The layers were separated and the organic layer was dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by column chromatography (SiO2, Et20) to afford 2-(4-benzenesulfonyl-pheny1)-4-benzyl-morpholine (0.28 g).
oTh 4-Benzy1-244-(toluene-2-sulfony1)-phenyll-morpholine: To a solution of 4-benzy1-6-(4-bromo-pheny1)-morpholine (0.55 g; 1.66 mmol) in THF (25 mL) was added drop wise a solution of n-BuLi in hexanes (1.32 ml; 2.50 molll; 3.31 mmol), at -78 C. The resulting mixture was stirred at -78 C, for 30 min. and then 2-methyl-benzenesulfonyl fluoride(0.63 g; 3.64 mmol) was added. After complete addition the mixture was allowed to come to room temperature, and treated with Et0Ac and a 5% aqueous NaHCO3-solution. The layers were separated and the organic layer was dried (Na2SO4), filtered, and concentrated in vacuo. The residue was purified by column chromatography (SiO2, Et20) to afford 4-benzy1-2-[4-(toluene-2-sulfony1)-phenyl]-morpholine (0.50 g). The required 2-methyl-benzenesulfonyl fluoride was prepared as follows: To a solution of o-toluenesulfonyl chloride (0.70 mL; 4.85 mmol) in CH3CN (15 mL) was added spray-dried KF (1.13 g; 19.4 mmol). The resulting mixture was stirred at RT for 18 hours, treated with water and extracted with CH2C12. The combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo to afford 2-methyl-benzenesulfonyl fluoride (0.68 g).
The following compounds were made according to a similar method:
4-Benzy1-244-(2-chloro-benzenesulfony1)-phenyll-morpholine 4-Benzy1-244-(2,6-dichloro-benzenesulfony1)-phenyll-morpholine WO 2912/094375 PCT/F,P2011/061590 S-Th Br 2-(4-Brorno-pheny1)-thiomorpholine-4-earboxylic acid tert-butyl ester:
To a solution of 2-(4-bromo-pheny1)-thiomorpho1ine (2.80 g; 10.85 mmol) in.
CII2C12 (50 mL) was added di-tert-butyl dicarbonate (2.60 g; 11.93 mmol), at.
0 C. After complete addition the mixture was allowed to warm to RT. and stirred overnight. Subsequently, the solvent was removed in vacuo and the residue purified by column chromatography (8i02, CHriC12) to afford 2-(4-bromo-pheny1)-thiomorpholine-4-carboxylic acid tert-butyl ester (3.61 g).
sTh 2-(44odo-pheny1)-thiomorpho1ine-4-carboxylic acid tert-butyl ester: To a degassed solution of 2-(4-bromo-phenyI)-thiomorpholine-4-carboxylic acid tert-butyl ester (0.75 g; 2.09 mmol) and N,A"-dimethylethylenediamine (0.11 taL; 1.05 mmol) in 1.4-dioxane (10 mL) was added Cul (39.9 mg; 0.21 mmol) and Na! (0.78 g; 5.23 mmol). The resulting mixture was heated in a closed vessel, at 180 C. for 3 days. After cooling to room temperature the mixture was concentrated in vacuo, and the residue was purified by column chromatography (SiO2, CII2C1Aexanes 1:1) to afford 2-(4-iodo-phenyl)-thiomorph.oline-4-carboxylic acid tert-butyl ester (0.35 g).
0=5"Th Br Ny0.<

2(4-Brumo-pheny1)-1,1-dioxo-1X- thiomorpholine-4-carboxylic acid _ tert-butyl ester: To a solution of 2-(4-bromo-phenyl)-thiomorpholine-4-carboxylic acid tert-butyl ester (3.60 g; 10.05 mmol) in CH2C12 (100 mL) was added 3-chloroperoxybenzoic acid (5.20 g; 30.14 mmol). at 0 C. The resulting mixture was stirred overnight at RT, and subsequently, a saturated aqueous sodium thiosulfate solution was added and the mixture stirred for another 30 5 min. The layers were separated and the aqueous layer was extracted twice with Et0Ac. The combined Et0Ae layers were washed twice with an aqueous Na2CO3 solution. The combined organic layers were dried (MgS0,1), filtered and concentrated in vacuo to afford 2.(4.1..tromo.pheny1).l.1-dioxa thiomorpholine-4-carboxylic acid tert-butyl ester (4.06 g) which was used as 10 such in the next step.
The following compound was made in a similar manner:

2-(4-lodo-phenyl)-1,1-dioxo-1X-thiomorpholine-4-carboxylic acid tert-butyl ester ci NH
(2,6-Dich1oro-pheny1)-(4-morpholin-2-311-phenyl)-amine : To a solution of [4-(4.berrzyl-morpholin.-2-0-pheny1]-(2.6.dichloro-pheny1)-amine (0.72 g; 1.74 mmol) in 1.2.dichloroethane (5 inL) was added, drop wise, ACE-C1 (0.40 inL;
3.66 unnol) at WC. The resulting mixture was stirred at room temperature, overnight., and subsequently concentrated in vacua. To the residue was added toluene and the mixture was concentrated in \WHO. This last step was repeated twice. To the final residue was added Meal" (5 m11,). and this mixture was stirred overnight, at. RT. Once more the mixture was concentrated in vacuo. The residue was partitioned between Et0Ac and 2 M. Aqueous Na0I1.
The layers were separated, and the organic layer dried (Na2SO4), filtered, and concentrated in vacuo to afford (2,6-dichloro-phenyl)-(4-morpholin-2-yl-phenyl)-amine (0.34 g); which was used as such.
The following compounds were made in a similar manner:
(2,6-Dimethyl-phenyl)-(4-morpholin-2-yl-phenyl)-amine[4-(4-Morpholin-2-y1)-pheny1]-(3-trifluoromethyl-phenyl)-methanone (2,6-Dimethyl-phenyl)-(4-morpholin-2-yl-phenyl)-methanone 244-(3-Trifluoromethyl-phenoxy)-phenyll-morpholine 2-(4-o-Tolyloxy-phenyl)-morpholine 244-(2,6-Dimethyl-phenoxy)-phenyll-morpholine (4-Morpholin-2-yl-phenyl)-o-tolyl-methanone (2,6-Dichloro-phenyl)-(4-morpholin-2-yl-phenyl)-methanone 243-Chloro-4-(2,6-dichloro-phenoxy)-phenyll-morpholine 244-(2,6-dimethyl-phenylsulfany1)-phenyll-morpholine 244-(2,3-dichloro-phenylsulfany1)-phenyll-morpholine 2-(4-o-Tolylsulfanyl-phenyl)-morpholine (jr"0 342-(4-Benzyloxy-phenyl)-5-oxo-morpholin-4-yll-propionic acid tert-butyl ester: To a mixture of 6-(4-benzyloxy-phenyl)-morpholin-3-one (13.40 g;
47.3 mmol) and powdered NaOH (3.78 g; 94.6 mmol) in THF (250 mL) was added tert-butyl acrylate (13.7 mL; 94.6 mmol). The resulting mixture was stirred at RT for 2 hours and subsequently concentrated in vacuo. The residue was purified by column chromatography (SiO2, Et20) to afford 3-[2-(4-benzyloxy-phenyl)-5-oxo-morpholin-4-y11-propionic acid tert-butyl ester (14.20 g).

O
NH
HO
4-Morpholin-2-yl-phenol: To a solution of 4-benzy1-2-(4-benzyloxy-pheny1)-morpholine (8.35 g; 23.2 mmol) in Me0H (100 mL) was added a catalytic amount of palladium hydroxide (0.65 g; -20 wt% on carbon, wet). The resulting mixture was treated with hydrogen (1 atm.) at RT, overnight. Subsequently, the mixture was filtered over kieselguhr, rinsed with Me0H, and concentrated in vacuo to afford 4-morpholin-2-yl-phenol (4.00 g), which was used as such.
The following compounds were made according to a similar method:
2-(4-Benzenesulfonyl-phenyl)-morpholine 244-(Toluene-2-sulfony1)-phenyl]-morpholine 244-(2-Chloro-benzenesulfony1)-phenyll-morpholine 244-(2,6-Dichloro-benzenesulfony1)-pheny1]-morpholine 4-Morpholin-2-y1-3-trifluoromethyl-phenol 3-Fluoro-4-morpholin-2-yl-phenol 4-(2-Methyl-morpholin-2-y1)-phenol 3-Morpholin-2-yl-phenol 4-(5,5-Dimethyl-morpholin-2-y1)-phenol 4-(6,6-Dimethyl-morpholin-2-y1)-phenol 342-(4-Hydroxy-pheny1)-5-oxo-morpholin-4-y11-propionic acid tert-butyl ester 1C) HO14110 Ny0.<

2-(4-Hydroxy-phenyl)-morpholine-4-carboxylic acid tert-butyl ester: A
mixture of 4-morpholin-2-yl-phenol (0.99 g; 5.41 mmol) and di-tert-butyl dicarbonate (1.18 g: 5.41 mmol) in CH3CN (50 mL) was stirred at ItT for 3 days. Subsequently. the resulting mixture was concentrated in yacuo and the residue was purified by column chromatography (SiO2, CH9C12:CH30H 97:3) to afford 2-(4-hydroxy-phenyl)-morpholine-4-carboxylic acid tert-butyl ester (1.15 g).
0-Th Ny 40) 0 2-14-(2,3-Dimethyl-phenoxy)-phenyl]-morpholine-4-carboxylic acid tert-butyl ester: To a degassod solution of 2-(4-hydroxy-phenyl)- morpholine-4-carboxylic acid tert-butyl ester (10.23 g; 36.6 mmol), and 1-iodo-2.3-dimethyl-benzene (10.62 g; 45.8 mmol) in DM80 (50 mL), was added picolinic acid (0,90 g; 7.3 mmol), CuI (0.70 g; 3.7 mmol) and K3PO4 (15.55 g; 73.3 mmol). The resulting mixture was heated overnight, at 90'C. After cooling to WI', brine was added and the mixture extracted with C112C12. The combined organic layers were dried (Na2SO4), filtered and concentrated in vacua. The residue was purified by column chromatography (S102. C11,C12) to afford 24442.3-dime.thyl-phenoxy)-phenyThmorpholine-4-carboxylic acid tert-butyl ester.
NH
2-(4-Iodo-phenyl)-thiomorpholine 1,1-dioxide: Acetyl chloride (2.8 mL
39.4 mmol) was added to ethanol (35 mL). The resulting solution was added to 2-(4-iodo-phenyl)-1,1-dioxo-1k-thiomorpholine-4-carboxylic acid tut-butyl ester (2.16 g; 4.94 mmol). at RT. The resulting mixture was stirred at 55'C
for 2 hours, and subsequently, at RT overnight, The resulting suspension was concentrated in vacuo, and treated with iPr20. The formed precipitate was collected by filtration and dried in vacuo to afford 2-(4-iodo-phenyl)- thiomorpholine 1,1-dioxide hydrochloride (1.78 g).
The following compound was made according to a similar method:
244-(2,3-Dimethyl-phenoxy)-phenyll-morpholine HO
342-(4-Hydroxy-pheny1)-morpholin-4-y11-propionic acid tert-butyl ester: A mixture of 4-morpholin-2-yl-phenol (3.95 g; 22.0 mmol), and tert-butyl acrylate (9.60 mL; 66.1 mmol) in CH3CN (100 mL) was heated under reflux overnight. After cooling to RT, the mixture was concentrated and purified by column chromatography (SiO2, Et20) to afford 342-(4-hydroxy-phenyl)-morpholin-4-yThpropionic acid tert-butyl ester (5.22 g).
The following compounds were made in a similar manner:
3-{214-(2,6-Dichloro-phenylamino)-phenyThmorpholin-4-yll-propionic acid tert-butyl ester 3-1214-(2,6-Dimethyl-phenylamino)-phenyl]-morpholin-4-yll-propionic acid tert-butyl ester 3-1214-(2,6-Dimethyl-benzoy1)-phenyl]-morpholin-4-yll-propionic acid tert-butyl ester 3-1214-(2,6-Dich1oro-benzoy1)-pheny1l-morpho1in-4-y1l-propionic acid tert-butyl ester 3-1214-(3-Trifluoromethyl-benzoy1)-phenyll-morpholin-4-yll-propionic acid tert-butyl ester 3-{214-(3-Trifluoromethy1-phenoxy)-pheny1]-morpholin-4-y1}-propionic acid tert-butyl ester 342-(4-o-Tolyloxy-phenyl)-morpholin-4-A-propionic acid tert-butyl ester 3-1214-(2,6-Dimethy1-phenoxy)-pheny1l-morpho1in-4-y1l-propionic acid tert-butyl ester 5 3-1214-(2-Methyl-benzoy1)-phenyl]-morpholin-4-y1}-propionic acid tert-butyl ester 342-(4-Hydroxy-2-trifluoromethyl-phenyl)-morpholin-4-yll-propionic acid tert-butyl ester.
342-(2-Fluoro-4-hydroxy-phenyl)-morpholin-4-yll-propionic acid tert-10 butyl ester.
342-(3-Hydroxy-pheny1)-morp1o1in-4-y11-propionic acid tert-butyl ester 342-(4-Hydroxy-phenyl)-5,5-dimethyl-morpholin-4-yll-propionic acid tert-butyl ester 15 .. 346-(4-Hydroxy-phenyl)-2,2-dimethyl-morpholin-4-yll-propionic acid tert-butyl ester 3-1213-Chloro-4-(2,6-dichloro-phenoxy)-phenyll-morpholin-4-yll-propionic acid tert-butyl ester 20 342-(4-Benzenesulfonyl-phenyl)-morpholin-4-yll-propionic acid tert-butyl ester.
3-1214-(Toluene-2-sulfony1)-phenyll-morpholin-4-y1}-propionic acid tert-butyl ester.
3-1214-(2-Chloro-benzenesulfony1)-phenyll-morpholin-4-y1}-propionic

25 acid tert-butyl ester 3-{214-(2,6-Dichloro-benzenesulfony1)-phenyll-morpholin-4-yll-propionic acid tert-butyl ester 342-(4-Hydroxy-phenyl)-2-methyl-morpholin-4-A-propionic acid tert-butyl ester 342-(4-Bromo-pheny1)-thiomorpholin-4-yll-propionic acid tert-butyl ester 3-[2-(4-Iodo-pheny1)-1,1-dioxo-1 6-thiomorpholin-4-yThpropionic acid tert-butyl ester 3-{24442,6-Dimethyl-phenylsulfany1)-phenyThmorpholin-4-yll-propionic acid tert-butyl ester 3-1214-(2,3-Dichloro-phenylsulfany1)-phenyll-morpholin-4-yll-propionic acid tert-butyl ester 342-(4-o-Tolylsulfanyl-pheny1)-morpholin-4-y11-propionic acid tert-butyl ester IJ sTh 342-(4-Iodo-pheny1)-thiomorpholin-4-yll-propionic acid tert-butyl ester: To a degassed solution of 312-(4-bromo-phenyl)-thiomorpholin-4-y1]-propionic acid tert-butyl ester (22.15 g; 57.33 mmol) and N,N'-dimethylethylenediamine (3.05 mL; 28.7 mmol) in 1,4-dioxane (250 mL) was added CuI (1.09 g; 5.73 mmol), and NaI (21.48 g; 143.33 mmol). The resulting mixture was heated at 130 C, for 4 days, in sealed flask. After cooling to RT
the mixture was concentrated in vacuol and purified by column chromatography (SiO2, Et20 / hexanes 2:3) to afford 312-(4-iodo-phenyl)-thiomorpholin-4-yli-propionic acid tert-butyl ester (19.30 g).
o¨

3-1214-(2,3-Dimethyl-phenoxy)-phenyll-morpholin-4-y1}-butyric acid tert-butyl ester: A mixture of 2-[4-(2,3-dimethyl-phenoxy)-phenyTh morpholine (1.00 g; 3.13 mmol), tert-butyl acetoacetate (2.07 mL; 12.5 mmol), sodium triacetoxyborohydride (1.86 g; 8.75 mmol), and a drop of acetic acid, in 1,2-dichloroethane (20 mL) was stirred overnight, at RT. The resulting mixture was treated with 5 % aqueous NaHCO3 and extracted with CH2C12.
The combined organic layers were dried (Na2SO4), filtered, concentrated in vacuo, and purified by column chromatography (SiO2, Et20 / hexanes 1:3) to afford 3-{2-[4-(2,3-dimethyl-phenoxy)-phenyl]-morpholin-4-yll-butyric acid tert-butyl ester (1.17 g 3-1244-(2,3-Dimethyl-phenoxy)-phenyll-morpholin-4-y11-2-methyl-propionic acid tert-butyl ester: A mixture of 214-(2,3-dimethyl-phenoxy)-phenyThmorpholine (0.60 g; 1.9 mmol), tert-butyl methacrylate (0.61 ml; 3.8 mmol), 1,8-diazabicyclo[5.4.0]undec-7-ene (0.84 ml; 5.6 mmol), and DMF (10 mL) was heated at 140 C, overnight, in a closed vessel. After cooling to room temperature, the mixture was partitioned between 5% aqueous NaHCO3 and Et0Ac. The organic layer was dried (MgSO4), filtered, and concentrated in vacuo. The residue was purified by column chromatography (SiO2, Et20 /
hexanes 1:9) to afford 3-{2-[4-(2,3-dimethyl-phenoxy)-phenyl]-morpholin-4-yll-2-methyl-propionic acid tert-butyl ester (0.27 g).

4-1214-(2,3-Dimethyl-phenoxy)-phenyll-morpholin-4-y1}-butyric acid tert-butyl ester: A mixture of 2-[4-(2,3-dimethyl-phenoxy)-pheny1]-morpholine (0.40 g; 1.2 mmol), K2CO3 (0.49 g; 3.6 mmol), KI (0.22 g; 1.31 mmol), 4-bromo-butyric acid tert-butyl ester (0.32 g; 1.43 mmol), and CH3CN
(30 mL), was heated under reflux, overnight. After cooling to RT the mixture was concentrated in vacuo, and the residue was purified by column chromatography (SiO2, Et20 / hexanes 1:1) to afford 4-{2- [4-(2,3-dimethyl-phenoxy)-pheny1]-morpholin-4-y1}-butyric acid tert-butyl ester (0.38 g).

342-(4-Phenoxy-phenyl)-morpholin-4-y1J-propionic acid tert-butyl ester: To a mixture of Cs2CO3 (70 mg; 0.21 mmol), 3-[2-(4-Hydroxy-pheny1)-morpholin-4-yl]-propionic acid tert-butyl ester (33.8 mg, 0.11 mmol) and bromobenzene (12,6 [IL, 0.12 mmol) was added 0.5 mL of a freshly prepared catalyst stock solution (see below) in a 2-5mL Biotage microwave vial. The vial was briefly flushed with N2 and sealed to maintain a semi-inert atmosphere. The resulting mixture was heated for 22h. at 140 C. After cooling to room temperature, water (5 mL) was added and the mixture was extracted with Et0Ac (1x7.5 mL, 2x5 mL). The combined organic layers were concentrated in vacuo. and the residue was purified by preparative TLC (SiO2, CH2C12/Me0H 99:1) to afford 3-p-(4-phenoxy-pheny1)-morpholin-4-y1]-propionic acid tert-butyl ester (49 mg). The catalyst stock solution was prepared as follows: To a suspension of copper(I)iodide (73 mg, 0.16 mmol) in anhydrous toluene (9 mL) was added 1-butylimidazole (12711L; 120 mg; 0.41 mmol). The solution was purged with N9 for 15 min. and vigorously agitated until all the CuI had fully dissolved.
The following compounds were prepared according to a similar method:
3-1214-(3-Trifluoromethoxy-phenoxy)-phenyll-morpholin-4-y11-propionic acid tert-butyl ester 3-{214-(3-F1uoro-5-trifluoromethy1-phenoxy)-pheny1]-morpholin-4-y1}-propionic acid tert-butyl ester 3-1214-(4-Morpholin-4-yl-phenoxy)-phenyl]-morpholin-4-yll-propionic acid tert-butyl ester 3-{244-(3-Chloro-4-methyl-phenoxy)-phenyl]-morpholin-4-yll-propionic acid tert-butyl ester 3-1214-(2,5-Bis-trifluoromethyl-phenoxy)-phenyll-morpholin-4-yll-propionic acid tert-butyl ester 3-1214-(2,4,6-Trifluoro-phenoxy)-phenyll-morpholin-4-y1}-propionic acid tert-butyl ester 3-{214-(Quino1in-3-y1oxy)-pheny1l-morpho1in-4-y1l-propionic acid tert-butyl ester 3-{214-(2,3-Difluoro-phenoxy)-pheny1]-morpho1in-4-y1}-propionic acid tert-butyl ester 3-1244-(4-Chloro-3-methyl-phenoxy)-phenyli-morpholin-4-yll-propionic acid tert-butyl ester 3-{244-(3-Difluoromethoxy-phenoxy)-phenyll-morpholin-4-yll-propionic acid tert-butyl ester 3-1214-(3-Dimethylamino-phenoxy)-phenyl]-morpholin-4-yll-propionic acid tert-butyl ester 3-1214-(1-0xo-indan-5-yloxy)-phenyl]-morpholin-4-y1}-propionic acid tert-butyl ester 3-{214-(Isoquino1in-5-y1oxy)-pheny1l-morpho1in-4-y1}-propionic acid tert-butyl ester 3-1214-(4-Ch1oro-2-methy1-phenoxy)-pheny1]-morpholin-4-y1}-propionic acid tert-butyl ester 3-1244-(4-Butyl-phenoxy)-phenyll-morpho1in-4-y1}-propionic acid tert-butyl ester 3-{244-(4-Chloro-3-trifluoromethyl-phenoxy)-phenyll-morpholin-4-y1}-propionic acid tert-butyl ester 3-{214-(Pyrimidin-2-y1oxy)-pheny1l-morpho1in-4-y1l-propionic acid tert-butyl ester 3-12[4-(Naphthalen-1-yloxy)-phenyl]-morpholin-4-yll-propionic acid tert-butyl ester 5 3-{244-(2-Fluoro-6-trifluoromethyl-phenoxy)-phenyll-morpholin-4-yll-propionic acid tert-butyl ester 3-1214-(4-Difluoromethoxy-phenoxy)-phenyll-morpholin-4-yll-propionic acid tert-butyl ester 3-12[4-(Pyridin-2-yloxy)-phenyl]-morpholin-4-yll-propionic acid tert-10 butyl ester 3-{214-(Isoquino1in-4-y1oxy)-pheny1l-morpho1in-4-y1}-propionic acid tert-butyl ester 3-{414-(2-tert-Butoxycarbonyl-ethyp-morpholin-2-y11-phenoxy}-benzoic acid methyl ester 15 3-1244-(2-Trifluoromethyl-phenoxy)-phenyli-morpholin-4-yll-propionic acid tert-butyl ester 342-(4-m-Tolyloxy-phenyl)-morpholin-4-A-propionic acid tert-butyl ester 3-1214-(3,5-Dimethyl-phenoxy)-phenyll-morpholin-4-y1}-propionic acid 20 tert-butyl ester 3-1214-(Pyridin-3-yloxy)-phenyll-morpho1in-4-y1}-propionic acid tert-butyl ester 3-{214-(4-F1uoro-phenoxy)-pheny1l-morpho1in-4-y1l-propionic acid tert-butyl ester 25 3-1214-(2,3-Dimethyl-phenoxy)-pheny1l-morpho1in-4-y1l-propionic acid tert-butyl ester 3-1244-(2,4-Difluoro-phenoxy)-phenyli-morpholin-4-yll-propionic acid tert-butyl ester 3-{244-(2,4-Dimethyl-phenoxy)-phenyll-morpholin-4-y1}-propionic acid 30 tert-butyl ester 3-{214-(2-Methoxy-phenoxy)-pheny1]-morpholin-4-y1}-propionic acid tert-butyl ester 3-1214-(3,5-Difluoro-phenoxy)-phenyThmorpholin-4-yll-propionic acid tert-butyl ester 3-{244-(1-0xo-1,3-dihydro-isobenzofuran-5-yloxy)-phenyThmorpholin-4-y1)-propionic acid tert-butyl ester 3-1214-(4-Methoxy-phenoxy)-phenyl]-morpholin-4-yll-propionic acid tert-butyl ester 3-1214-(3,4-Dimethyl-phenoxy)-phenyll-morpholin-4-y1}-propionic acid tert-butyl ester 3-{214-(4-Trifluoromethy1-phenoxy)-phenyll-morpholin-4-y1}-propionic acid tert-butyl ester 3-{214-(2,5-Dimethy1-phenoxy)-pheny1l-morpho1in-4-y1l-propionic acid tert-butyl ester 3-1244-(3-Fluoro-phenoxy)-phenyll-morpho1in-4-y1l-propionic acid tert-butyl ester 3-{244-(3-Methoxy-phenoxy)-phenyl]-morpholin-4-yll-propionic acid tert-butyl ester 3-1214-(Benzo11,31dioxol-5-yloxy)-phenyll-morpholin-4-yll-propionic acid tert-butyl ester 3-1214-(3-Fluoro-4-methyl-phenoxy)-phenyl]-morpholin-4-yll-propionic acid tert-butyl ester 3-{214-(4-Methanesu1fony1-phenoxy)-pheny1l-morpholin-4-yll-propionic acid tert-butyl ester 3-1214-(4-Acety1-phenoxy)-pheny1l-morpho1in-4-y1l-propionic acid tert-butyl ester 3-12L4-(Bipheny1-4-yloxy)-phenyli-morpholin-4-yll-propionic acid tert-butyl ester 3-{244-(4-Benzyloxy-phenoxy)-phenyl]-morpholin-4-y1}-propionic acid tert-butyl ester 3-{214-(4-Trifluoromethoxy-phenoxy)-phenyll-morpholin-4-yll-propionic acid tert-butyl ester 3-1214-(2-Trifluoromethoxy-phenoxy)-phenyll-morpholin-4-yll-propionic acid tert-butyl ester 3-{244-(2-Acetylamino-phenoxy)-phenyl]-morpholin-4-y1}-propionic acid tert-butyl ester 3-1214-(2-Fluoro-phenoxy)-phenyll-morpholin-4-y1}-propionic acid tert-butyl ester 3-1214-(2,5-Difluoro-phenoxy)-phenyll-morpholin-4-yll-propionic acid tert-butyl ester 3-{214-(2,3-Dich1oro-phenoxy)-pheny1l-morpho1in-4-y1}-propionic acid tert-butyl ester 342-(4-p-Tolyloxy-pheny1)-morpholin-4-A-propionic acid tert-butyl ester 3-1244-(3,4-Dichloro-phenoxy)-phenyThmorpholin-4-y1}-propionic acid tert-butyl ester 3-{244-(3,5-Bis-trifluoromethyl-phenoxy)-phenyll-morpholin-4-yll-propionic acid tert-butyl ester 3-1214-(3,5-Dich1oro-phenoxy)-pheny11-morpho1in-4-y1}-propionic acid tert-butyl ester 3-1214-(Naphtha1en-2-y1oxy)-pheny1]-morpho1in-4-y1}-propionic acid tert-butyl ester 3-{214-(2,6-Dimethyl-phenoxy)-pheny11-5-oxo-morpholin-4-y1}-propionic acid tert-butyl ester o 0 N.(0,..<

3-{214-(2,3-Dimethyl-phenoxy)-pheny11-2-methyl-morpholin-4-y1}-propionic acid tert-butyl ester: To a degassed solution of 3-[2-(4-hydroxy-pheny1)-2-methyl-morpholin-4-y1]-propionic acid tert-butyl ester (1.07 g; 3.33 mmol), and 3-iodo-o-xylene (0.97 g; 4.16 mmol) in DMSO (20 mL) was added picolinic acid (82 mg; 0.67 mmol), CuI (63.4 mg; 0.33 mmol) and powdered (1.41 g; 6.66 mmol). The resulting mixture was heated for 24 h, at 90 C. After .. cooling to room temperature, brine was added and the mixture extracted with CH2C12. The combined layers were dried (Na2SO4), filtered, and concentrated in vacuo. The residue was purified by column chromatography (SiO2, Et20/hexanes 1:1) to afford 3-1214-(2,3-dimethyl-phenoxy)-pheny1]-2-methyl-morpholin-4-y1}-propionic acid tert-butyl ester (1.32 g).
CI

CI
3-1214-(2,6-Dich1oro-phenoxy)-pheny1l-morpho1in-4-y1}-propionic acid tert-butyl ester: A mixture of 3-[2-(4-hydroxy-pheny1)-morpholin-4-y1]-propionic acid tert-butyl ester (200 mg; 0.65 mmol). 2,6-dichlorofluorobenzene (107.35 mg; 0.65 mmol) and K2CO3 (134.9 mg; 0.98 mmol), in DMF (10 mL) was heated at 100 C, for 2 days. After cooling to RT the mixture was diluted with Et20 and washed with water (3 times). The combined organic layers were dried (Na9SO4), filtered, and concentrated in vacuo. The residue was purified by column chromatography (Et20) to afford 3-1214-(2,6-dichloro-phenoxy)-phenyThmorpholin-4-yll-propionic acid tert-butyl ester: (150.00 mg).
The following compounds were prepared according to a similar method:
3-1244-(2,6-Dichloro-phenoxy)-pheny1]-5,5-dimethyl-morpholin-4-y11-propionic acid tert-butyl ester 3-{644-(2,6-Dichloro-phenoxy)-pheny11-2,2-dimethyl-morpholin-4-yll-propionic acid tert-butyl ester 3-1214-(2,6-Dichloro-phenoxy)-2-fluoro-phenyll-morpholin-4-yll-propionic acid tert-butyl ester 3-{214-(2,6-Dichloro-phenoxy)-2-trifluoromethyl-phenyll-morpholin-4-y1}-propionic acid tert-butyl ester 3-1214-(2,6-Dichloro-phenoxy)-pheny11-2-methyl-morpholin-4-y11-propionic acid tert-butyl ester sTh s CI 0 Nr 3-{214-(2-Ch1oro-phenoxy)-phenyll-thiomorpholin-4-yll-propionic acid tert-butyl ester: To a degassed solution of 342-(4-iodo-phenyl)-thiomorpholin-4-y1]-propionic acid tert-butyl ester (0.40 g; 0.92 mmol), and 2-chlorophenol (0.28 g; 2.22 mmol) in DMSO, was added picolinic acid (22.7 mg; 0.18 mmol), CuI (17.6 mg; 0.09 mmol) and K3PO4 (0.78 g; 3.69 mmol). The resulting mixture was heated overnight, at 90 C. After cooling to RT, water was added and the mixture extracted with C112C12. The organic layer was dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by column chromatography (SiO2, Et20 / hexanes 1:2) to afford 3-{214-(2-Chloro-phenoxy)-phenyl]-thiomorpholin-4-y1}-propionic acid tert-butyl ester (0.15 g).
The following compounds were prepared according to a similar method:
3-1214-(2,3-Dimethyl-phenoxy)-pheny1l-thiomorpho1in-4-y1}-propionic acid tert-butyl ester 3-1244-(2-Chloro-6-methyl-phenoxy)-phenyli-thiomorpholin-4-y11-propionic acid tert-butyl ester The following compound was prepared according to a similar method from 3-[2-(4-iodo-phenyl)-1,1-dioxo-106-thiomorpholin-4-y1]-propionic acid tert-butyl ester:
3-1214-(2,3-Dimethyl-phenoxy)-pheny11-1,1-dioxo-1U6-thiomorpholin-4-y1}-propionic acid tert-butyl ester 0:
sTh s C0I

3-1244-(2-Chloro-phenoxy)-pheny11-1-oxo-thiomorpholin-4-yll-propio-nic acid tert-butyl ester: To a solution of 3-1214-(2-Chloro-phenoxy)-pheny1]-thiomorpholin-4-yll-propionic acid tert-butyl ester (0.28 g; 0.65 mmol) in 5 Me0H (10 mL) was added ,dropwise, a solution of OXONE"- (0.20 g; 0.32 mmol) in water (10 mL), at 0 C. The mixture was stirred for 2 hours at 0 C, and then allowed to warm to room temperature overnight. Subsequently, water, brine, and 25% aqueous NH4OH were added and the mixture extracted with Et0Ac. The combined organic layers were dried (Na2SO4), filtered and 10 .. concentrated in vacuo. The residue was purified by column chromatography (SiO2, CH2C12 / Me0H 98:2) to afford 3-{244-(2-Chloro-phenoxy)-pheny1]-1-oxo-thiomorpholin-4-yll-propionic acid tert-butyl ester (0.19 g).
The following compound was made in a similar manner:
15 3-{244-(2,3-Dimethyl-phenoxy)-pheny11-1-oxo-thiomorpholin-4-y1}-propionic acid tert-butyl ester 4. SYNTHESES OF SPECIFIC COMPOUNDS
(See Table 1) Method A:
Compound 1: 3-{244-(2,6-Dichloro-phenylamino)-phenyll-morpholin-4-y1}-propionic acid hydrochloride: 3-{244-(2,6-Dichloro-phenylamino)-phenyThmorpholin-4-yll-propionic acid tert-butyl ester (0.36 g; 0.80 mmol) was treated with HC1 in 1,4-dioxane (3.99 mL; 4.00 mol/L; 15.95 mmol) and stirred overnight at room temperature. The solvent was removed in vacuo and the residue treated with iPr20. The formed precipitate was collected by filtration and dried in vacuo, overnight to afford 3-12- [4-(2,6-Dichloro-phenylamino)-phenyfl-morpholin-4-y11-propionic acid hydrochloride (0.30 g). 111 NMR (400 MHz, DMSO-d6) 0 ppm 2.83 - 2.98 (1 H, m) 2.98 - 3.20 (1 H, m) 3.21 - 3.36 (1 H, m)3.38 - 3.48 (1 H, m) 3.49 - 3.55 (1 H, m) 3.97 (1 H, t, J=12.6 Hz) 4.04 -4.18 (1 H, m) 4.72 (1 H, d) 6.53 (1 H, d) 7.14 (1 H, d) 7.29 (1 H, t, J=8.1 Hz) 7.57 (1 H, d) 8.03 (1 H, s).
The following compounds were made in a similar manner:
Compound 2: 34244-(2,6-Dimethyl-phenylamino)-phenyll-morpholin-4-y1}-propionic acid hydrochloride. 1H NMR (400 MHz, DMSO-d6) 0 ppm 2.12 (s, 6 H) 2.85 - 2.94 (m, 2 H) 3.02 - 3.14 (m, 2 H) 3.27 - 3.35 (m, 2 H) 3.40 -3.54 (m, 2 H) 3.92 - 4.12 (m, 2 H) 4.70 (d, J=11.3 Hz, 1 H) 6.40 (d, J=8.8 Hz, H) 7.05 - 7.15 (m, 5 H) 7.50 (bs, 1 H) 11.8 (bs, 1 H) 12.8 (bs, 1 H).
Compound 3: 3-{244-(2,6-Dimethyl-benzoy1)-phenyll-morpholin-4-y1}-propionic acid hydrochloride: 1H NMR (300 MHz, CD30D) I ppm 2.09 (s, 6 H), 2.91 (t, J= 7 Hz, 2 H) 3.13 (t, J=12 Hz, 1 H) 3.51 (t, J= 7 Hz, 2 H) 3.62 (d, J=12 Hz, 1 H) 3.76 (d, J=12 Hz, 1 H) 4.0 - 4.1 (m, 1 H) 4.32 (dd, J=13 Hz J=3 Hz, 1H) 4.93 (bd. J= 12 Hz, 1 H) 7.15 (d, J=8 Hz, 2 H), 7,30 (dd, J=8 Hz, 1 H) 7.61 (d, J=8 Hz, 2 H), 7.82 (d, J=8 Hz, 2 H).
Compound 4: 3-{244-(3-Trifluoromethyl-benzoy1)-phenyll-morpholin-4-y1}-propionic acid hydrochloride 1H NMR (300 MHz, CD30D) I ppm 2.95 (t, J= 7 Hz, 2 H) 3.19 (t, J=12 Hz, 1 H) 3.54 (t, J= 7 Hz, 2 H) 3.6- 3.8 (m, 1 H) 3.82 (d, J=13 Hz, 1 H) 4.09 (t, J= 12 Hz, 1 H) 4.3 - 4.4 (m, 1H) 4.9 - 5.0 (m, H) 7.66 (d, J=8 Hz, 2 H), 7.78 (t, J= 8 Hz, 1 H) 7.86 (d, J= 8 Hz, 2 H) 7.9 -8.1 (m, 3 H).
Compound 5: 3-1244-(2-Methyl-benzoy1)-phenyll-morpholin-4-y1}-propionic acid hydrochloride 11-1 NMR (300 MHz, CD30D) I ppm 2.30 (s, 3 H) 2.93 (t, J= 7 Hz, 2 H) 3.16 (dd. J=12 Hz J=12 Hz, 1 H) 3.53 (t, J= 7 Hz, 2 H) 3.64 (d, J=12 Hz, 1 H) 3.78 (d, J=12 Hz, 1 H) 4.07 (dt, J= 13 Hz J= 2 Hz, 1 H) 4.33 (dd, J=13 Hz J=3 Hz, 1H) 4.95 (dd, J= 12 Hz J= 2 Hz, 1 H) 7.3 - 7.5 (m, 3 H), 7.61 (d, J=8 Hz, 2 H), 7.82 (d, J=8 Hz, 2 H).
Compound 6: 34244-(2,6-Dich1oro-benzoy1)-pheny1]-morpho1in-4-y1}-propionic acid hydrochloride 1H NMR (300 MHz, CD30D) ppm 2.92 (t, J= 7 Hz, 2 H) 3.14 (t, J=12 Hz, 1 H) 3.60 - 3.68 (m, 2 H) 3.76 - 3.80 (m, 1 H) 4.06 (t, J= 13 Hz, 1 H) 4.33 (dd, J=13 Hz J=3 Hz, 1H) 4.95 (d, J= 11 Hz, 1 H) 7.53 - 7.55 (m, 3 H), 7.64 (d, J=8 Hz, 2 H), 7.85 (d, J=8 Hz, 2 H).
Compound 7: 312-(4-o-Tolyloxy-phenyl)-morpholin-4-yll-propionic acid hydrochloride 1H NMR (300 MHz, CD30D) ppm 2.17 (s, 3 H) 2.90 (t, J= 7 Hz, 2 H) 3.14 (t, J=12 Hz, 1 H) 3.2- 3.3 (m, 1H) 3.49 (t, J= 7 Hz, 2 H) 3.5 -3.7 (m, 2 H) 4.01 (t, J= 12 Hz, 1 H) 4.2 - 4.3 (m, 1H) 4.7 - 4.8 (m, 1 H) 6.8 -6.9 (m, 3 H) 7.0 - 7.4 (m, 5 H).
Compound 8: 3-{244-(3-Trifluoromethyl-phenoxy)-phenyll-morpholin-4-yll-propionic acid hydrochloride 1H NMR (300 MHz, CD30D) P1 ppm 2.90 (t, J= 7 Hz, 2 H) 3.15 (t, J=12 Hz, 1 H) 3.50 (t, J= 7 Hz, 2 H) 3.59 (d, J=12 Hz, 1 H) 3.69 (d, J=13 Hz, 1 H) 4.02 (t, J= 13 Hz, 1 H) 4.28 (dd, J=13 Hz J=3 Hz, 1H) 4.7 - 4.9 (m, 1 H) 7.09 (d, J=8 Hz, 2 H), 7.2 - 7.3 (m, 2 H) 7.4 - 7.6 (m, 4H).
Compound 9: 3-1244-(2,6-Dimethyl-phenoxy)-phenyli-morpholin-4-yll-propionic acid hydrochloride 1H NMR (300 MHz, CD30D) 0 ppm 2.07 (s, 6 H), 2.88 (t, J= 7 Hz, 2 H) 3.13 (t, J=12 Hz, 1 H) 3.2 - 3.3 (m, 1 H) 3.48 (t, J= 7 Hz, 2 H) 3.58 (d, J=13 Hz, 1 H) 3.99 (t, J=12 Hz, 1 H) 4.24 (dd, J=13 Hz J=3 Hz, 1H) 4.7 - 4.8 (m, 1 H) 6.75 (d, J= 9 Hz, 2 H) 7.0 - 7.2 (m, 3 H), 7.34 (d.
J=9 Hz, 2 H).
Compound 10: 3-{ 2-acid hydrochloride '1-1 NMR (400 MHz, DMSO-d6) 0 ppm 2.87 (2 H, ddd, J=11.8, 3.7, 3.5 Hz) 3.02 - 3.18 (2 H, m) 3.32(2 H, t, J=8.5 Hz) 3.47 (2 H, dd, J=13.3, 1.1 Hz) 3.58 - 3.67 (1 H, m) 3.97 (1 H, t, J=12.5 Hz) 4.10 -4.19 (1 H, m) 4.80 (1 H, d, J=11.6 Hz) 6.83 - 6.89 (2 H, m) 7.34 - 7.43 (3 H, m) 7.67 (2 H, d, J=8.3 Hz).

Compound 69: 3-{213-Chloro-4-(2,6-dichloro-phenoxy)-phenyll-morpholin-4-y1}-propionic acid hydrochloride Mp = 224 - 227 C.
Compound 70: 3-{214-(2,6-Dichloro-phenoxy)-2-fluoro-phenyl]-morpholin-4-yll-propionic acid hydrochloride Mp = 207 - 209 C.
Compound 71: 3-{ 2-acid hydrochloride Mp = 135 -136 C.
Compound 72: 3-{244-(2,6-Dichloro-phenoxy)-pheny1]-5,5-dimethyl-morpholin-4-y1}-propionic acid hydrochloride 1H NMR (400 MHz, DMSO-d6) H ppm 1.41 (s, 6 H) 2.90 - 3.02 (m. 3 H) 3.12 - 3.23 (m, 1 H) 3.53 -3.63 (m, 2 H) 3.77 - 3.83 (m, 1 H) 3.94 - 4.00 (m, 1 H) 4.96 (dd, J=11.3, 2.6 Hz, 1 H) 6.85 (d. J=8.8 Hz, 2 H) 7.36 - 7.44 (m, 3 H) 7.67 (d. J=8.1 Hz, 2 H) 11.2 (bs, 1 H) 12.7 (bs, 1 H).
Compound 73: 3-1644-(2,6-Dichloro-phenoxy)-phenyl]-2,2-dimethyl-morpholin-4-yll-propionic acid 111 NMR (400 MHz, DMSO-d6) H ppm 1.26 (s, 3 H) 1.49 (s, 3 H) 2.83 - 2.93 (m, 2 H) 3.25 - 3.34 (m, 2 H) 3.35 - 3.55 (m, 4 H) 4.92 (d, J=11.0 Hz, 1 H) 6.85(d, J=8.8 Hz, 2 H) 7.33 - 7.42 (m, 3 H) 7.67 (d, J=8.1 Hz, 2 H) 10.5 (bs, 1 H) 12.9 (bs, 1 H).
Compound 74: 342-(4-Benzenesulfonyl-phenyl)-morpholin-4-yll-propionic acid hydrochloride '1-1 NMR (400 MHz, DMSO-d6) H ppm 2.85 -2.92 (m, 2 H) 2.95 - 3.05 (in, 1 H) 3.06 - 3.19 (m, 1 H) 3.21 - 3.38 (m, 2 H) 3.45 - 3.52 (m, 1 H) 3.65 - 3.72 (m, 1 H) 3.98 - 4.08 (m, 1 H) 4.18 (d, J=11.0 Hz, 1 H) 4.97 (d, J=11.0 Hz, 1 H) 7.61 - 7.73 (m, 5 H) 7.93 - 8.05 (m, 4 H) 11.5 (bs, 1 H) 12.8 (bs, 1 H) Compound 75: 3-{214-(Toluene-2-sulfony1)-phenyll-morpholin-4-yll-propionic acid hydrochloride 1H NMR (400 MHz, DMSO-d6) LI ppm 2.37 (s, 3 H) 2.87 - 2.93 (m, 2 H) 2.97 - 3.07 (m, 1 H) 3.08 - 3.19 (m, 1 H) 3.24 -3.36 (m, 2 H) 3.49 (d, J=11.0 Hz, 1 H) 3.71 (d, J=11.0 Hz, 1 H) 4.00 - 4.10 (m, 1 H) 4.14 - 4.22 (m, 1 H) 5.01 (d, J=10.7 Hz, 1 H) 7.39 (d, J=7.7 Hz, 1 H) 7.50 -7.58 (m, 1 H) 7.59 - 7.67 (m, 3 H) 7.92 (d, J=8.5 Hz, 2 H) 8.13 (dd, J=7.7, 1.5 Hz, H) 11.8 (bs, 1 H) 12.6 (bs, 1 H).
Compound 76: 3-{214-(2-Chloro-benzenesulfony1)-phenyll-morpholin-4-yll-propionic acid hydrochloride 1H NMR (400 MHz, DMSO-d6) 0 ppm 2.85 - 2.91 (m, 2 H) 2.98 - 3.09 (m, 1 H) 3.09 - 3.19 (m, 1 H) 3.22 - 3.38 (m, 2 H) 3.49 (d, J=11.8 Hz, 1 H) 3.73 (d, J=11.8 Hz, 1 H) 3.98 - 4.10 (m, 1 H) 4.15 -4.23 (m, 1 H) 5.01 (d, J=11.4 Hz, 1 H) 7.63 - 7.78 (m, 5 H) 7.97 (d, J=8.5 Hz, 2 H) 8.31 (dd, J= 7.8, 1.8 Hz, 1 H) 11.6 (bs, 1 H) 12.7 (bs, 1 H).
Compound 77: 3-{214-(2,6-Dichloro-benzenesulfony1)-phenyll-morpholin-4-yll-propionic acid hydrochloride 1H NMR (400 MHz, DMSO-d6) 0 ppm 2.82 - 2.91 (m., 2 H) 2.96 - 3.09 (m, 1 H) 3.09 - 3.19 (m, 1 H) 3.39 - 3.55 (m, 3 H) 3.73 (d, J=11.8 Hz, 1 H) 3.96 - 4.08 (m, 1 H) 4.15 - 4.24 (m, 1 H) 4.99 (d, J=11.9 Hz, 1 H) 7.62 - 7.73 (m, 5 H) 8.03 (d, J=8.3 Hz, 2 H) 11.2 (bs, 1 H) 12.6 (bs, 1 H) Compound 78: 3-1214-(2,6-Dimethyl-phenoxy)-phenyll-5-oxo-morpholin-4-yll-propionic acid 1H NMR (400 MHz, DMSO-d6) P1 ppm 2.05 (s, 6 H) 2.47 - 2.55 (m, 2 H) 3.39 - 3.62 (m, 4 H) 4.20 (s, 2 H) 4.77 - 4.83 (m, 1 H) 6.73 (d, J=8.7 Hz, 2 H) 7.08 - 7.20 (m, 3 H) 7.33 (d, J=8.7 Hz, 2 H) 12.5 (bs, 1H).
Compound 79: 3-{214-(2,6-Dichloro-phenoxy)-phenyl]-2-methyl-morpholin-4-yll-propionic acid hydrochloride 1H NMR (400 MHz, DMSO-d6) 0 ppm 2.82 - 3.74 (m, 11 H) 3.95 - 4.15 (m, 2 H) 6.85 (br. s., 2 H) 7.36 - 7.43 (m, 1 H) 7.47 (d, J=8.5 Hz, 2 H) 7.67 (d, J=8.5 Hz, 2 H) 10.88 -11.13 (br. s., 1 H) 12.58- 13.03 (br. s., 1 H).
Compound 80: 3-1244-(2,3-Dimethyl-phenoxy)-phenyl]-2-methyl-morpholin-4-yll-propionic acid hydrochloride 1H NMR (400 MHz, DMSO-d6) 0 ppm 2.07 (s, 3H) 2.28 (s, 3E1) 2.82 - 3.74 (m, 11 H) 3.95 - 4.15 (m, 2 H) 6.73 - 6.90 (m., 3 H) 7.03 (d, J=8.5 Hz, 1 H) 7.12 (t, J=8.5 Hz, 1 H) 7.45 (d, J=8.5 Hz, 2 H) 10.88 - 11.13 (br. s., 1 H) 12.58 - 13.03 (br. s., 1 H).

Compound 81: 3-{214-(2,6-Dimethyl-phenylsulfany1)-phenyll-morpholin-4-y1}-propionic acid hydrochloride 1H NMR (400 MHz, DMSO-d6) 0 ppm 2.35 (s, 6 H) 2.85 - 2.96 (m, 2 H) 2.99 - 3.17 (m, 2 H) 3.31 (br.
s., 2 H) 3.46 (d, J=12.3 Hz, 1 H) 3.53 - 3.63 (m, 1 H) 3.94 - 4.17 (m, 2 H) 4.82 (d, 5 J=10.5 Hz, 1 H) 6.92 (d, J=8.3 Hz, 2 H) 7.23 - 7.36 (m, 5 H) 11.0 - 12.9 (m, 2H).
Compound 82: 3-{214-(2,3-Dichloro-phenylsulfany1)-phenyll-morpholin-4-yll-propionic acid hydrochloride 1H NMR (400 MHz, DMSO-d6) 0 ppm 2.82 - 2.96 (m, 2 H) 3.03 - 3.21 (in, 2 H) 3.34 (hr. s., 2 H) 3.50 (d, J=11.7 Hz, 1 H) 3.70 (d, J=11.7 Hz, 1 H) 3.98 - 4.10 (m, 1 H) 4.18 (d, J=11.7 10 Hz, 1 H) 4.94 (d, J=10.5 Hz, 1 H) 6.86 (d, J=8.0 Hz, 1 H) 7.29 (t, J=8.0 Hz, 1 H) 7.46 - 7.58 (m, 5 H) 11.0 - 12.9 (in, 2H).
Compound 83: 342-(4-o-Tolylsulfanyl-pheny1)-morpholin-4-y11-propionic acid hydrochloride 1H NMR (400 MHz, DMSO-d6) P1 ppm 2.32 (s, 3 H) 2.85 - 2.92 (in, 2 H) 2.99 - 3.17 (m, 2 H) 3.31 (hr. s., 2 H) 3.44 (d, J=12.4 15 Hz, 1 H) 3.58 - 3.68 (m, 1 H) 3.94 - 4.04 (m, 1 H) 4.12 - 4.20 (m, 1H) 4.82 (d, J=10.5 Hz, 1 H) 7.18 - 7.40 (in, 8 H) 11.0 - 12.9 (m, 2H).
Compound 84: 3-{ 2-acid hydrochloride Mp = 219 - 223 C.
Compound 85: 3-{244-(2,3-Dimethyl-phenoxy)-phenyll-morpholin-4-y1}-20 butyric acid hydrochloride: Mp = 165 - 170 C.
Compound 86: 3-{244-(2,3-Dimethyl-phenoxy)-phenyll-morpholin-4-y1}-2-methyl-propionic acid hydrochloride: Mp = 177 - 180 C.
Compound 87: 4-{214-(2,3-Dimethyl-phenoxy)-phenyll-morpholin-4-y1}-butyric acid hydrochloride: Mp = 225 - 227 C.
25 Compound 88: 3-{ 2-acid hydrochloride Mp = 155 - 160 C.
Compound 89: 3-{ 2-acid hydrochloride Mp = 178 - 183 C.
Compound 90: 3-{214-(2-Chloro-6-methyl-phenoxy)-phenyll-30 thiomorpholin-4-y1}-propionic acid hydrochloride Mp = 192.5 - 195 C.

Compound 93: 3-{214-(2,3-Dimethyl-phenoxy)-phenyl]-1,1-dioxo-1 6-thiomorpholin-4-y1}-propionic acid 1H NMR (400 MHz, DMSO-c16) 0 ppm 2.07 (s, 3H), 2.29 (s, 3H), 2.41 (t, J = 7Hz, 2H), 2.78-2.91 (m, 3 H), 3.05-3.30 (m, 5H), 4.42 (dd, J = 12 and 4 Hz, 1H), 6.80 (d, J = 8 Hz, 1H), 6.84 (d, J =

Hz, 2H), 7.06 (d, J = 8 Hz, 1H), 7.13 (t, J = 8 Hz, 1H), 7.36 (d, J = 8 Hz, 2H), 12.00-12.70 (bs, 1H).
Method B:
Compound 11: 342-(4-Phenoxy-phenyl)-morpholin-4-y11-propionic acid hydrochloride: 342-(4-Phenoxy-pheny1)-morpholin-4-yThpropionic acid tert-butyl ester (49 mg) was treated with HC1 in 1,4-dioxane (0.5 mL; 4.0 mol/L, 2 mmol) and shaken overnight at room temperature. Removal of the solvent in v acuo yielded 342-(4-phenoxy-pheny1)-morpholin-4-A-propionic acid hydrochloride as an amorphous broken white powder (48 mg). Rt = 1.60 min.
The following compounds were prepared according to a similar method:
Compound 12: 3-{244-(3-Trifluoromethoxy-phenoxy)-phenyTh morpholin-4-yl}-propionic acid hydrochloride Rt = 1.89 min.
Compound 13: 3-{ 2-morpholin-4-yll-propionic acid hydrochloride Rt = 1.76 min.
Compound 14: 3-{ 2-acid hydrochloride Rt = 1.52 min.
Compound 15: 3-{214-(3-Chloro-4-methyl-phenoxy)-phenyll-morpholin-4-yll-propionic acid hydrochloride Rt = 1.78 min.
Compound 16: 3-{214-(2,5-Bis-trifluoromethyl-phenoxy)-phenyll-morpholin-4-y1}-propionic acid hydrochloride Rt = 1.80 min.
Compound 17: 3-{ 2-acid hydrochloride Rt = 1.66 min.
Compound 18: 3-{214-(Quinolin-3-yloxy)-phenyll-morpholin-4-y11-propionic acid hydrochloride Rt = 1.56 min.

Compound 19: 3-{ 2-acid hydrochloride Rt = 1.65 min.
Compound 20: 3-{214-(4-Chloro-3-methyl-phenoxy)-phenyll-morpholin-4-yll-propionic acid hydrochloride Rt = 1.76 min.
Compound 21: 3-{ 2-acid hydrochloride Rt = 1.69 min.
Compound 22: 3-{244-(3-Dimethylamino-phenoxy)-phenyli-morpholin-4-yl}-propionic acid hydrochloride Rt = 1.56 min.
Compound 23: 3-{2-[4-(1-0xo-indan-5-yloxy)-phenyl]-morpholin-4-yll-propionic acid hydrochloride Rt = 1.49 min.
Compound 24: 3-{244-(Isoquinolin-5-yloxy)-phenyll-morpholin-4-yll-propionic acid hydrochloride Rt = 1.32 min.
Compound 25: 3-{214-(4-Chloro-2-methyl-phenoxy)-phenyll-morpholin-4-yll-propionic acid hydrochloride Rt = 1.76 min.
Compound 26: 3-{ 2-acid hydrochloride Rt = 1.92 min.
Compound 27: 3-{ 2-acid hydrochloride Rt = 1.81 min.
Compound 28: 3-{214-(Pyrimidin-2-yloxy)-phenyll-morpho1in-4-y1}-propionic acid hydrochloride Rt = 1.31 min.
Compound 29: 3-{ 2-acid hydrochloride Rt = 1.73 min.
Compound 30: 3-{ 2-acid hydrochloride Rt = 1.70 min.
Compound 31: 3-{ 2-acid hydrochloride Rt = 1.68 min.
Compound 32: 3-{214-(Pyridin-2-yloxy)-phenyll-morpholin-4-yll-propionic acid hydrochloride Rt = 1.41 min.
Compound 33: 3-1214-(Isoquinolin-4-yloxy)-phenyll-morpholin-4-yll-propionic acid hydrochloride Rt = 1.42 min.

Compound 34: 3-{414-(2-Carboxy-ethyp-morpholin-2-y11-phenoxy}-benzoic acid methyl ester hydrochloride Rt = 1.63 min.
Compound 35: 3-{214-(2-Trifluoromethyl-phenoxy)-phenyll-morpholin-4-yll-propionic acid hydrochloride Rt = 1.71 min.
Compound 36: 342-(4-m-Tolyloxy-phenyl)-morpholin-4-yll-propionic acid hydrochloride Rt = 1.66 min.
Compound 37: 3-{ 2-acid hydrochloride Rt = 1.73 min.
Compound 38: 3-{2-[4-(Pyridin-3-yloxy)-phenyll-morpholin-4-yll-propionic acid hydrochloride Rt = 1.31 min.
Compound 39: 3-{244-(4-Fluoro-phenoxy)-phenyll-morpholin-4-y11-propionic acid hydrochloride Rt = 1.61 min.
Compound 40: 3-{214-(2,3-Dimethyl-phenoxy)-phenyll-morpholin-4-y1}-propionic acid hydrochloride Rt = 1.74 min.
Compound 41: 3-{ 2-acid hydrochloride Rt = 1.64 min.
Compound 42: 3-{ 2-acid hydrochloride Rt = 1.74 min.
Compound 43: 3-{ 2-propionic acid hydrochloride Rt = 1.57 min.
Compound 44: 3-{ 2-acid hydrochloride Rt = 1.66 min.
Compound 45: 3-{214-(1-0xo-1,3-dihydro-isobenzofuran-5-yloxy)-phenyll-morpholin-4-y1}-propionic acid hydrochloride Rt = 1.47 min.
Compound 46: 3-{ 2-acid hydrochloride Rt = 1.59 mill.
Compound 47: 3-{214-(3,4-Dimethyl-phenoxy)-phenyll-morpholin-4-y1}-propionic acid hydrochloride Rt = 1.74 min.
Compound 48: 3-{ 2-4-yll-propionic acid hydrochloride Rt = 1.77 min.

Compound 49: 3-{214-(2,5-Dimethyl-phenoxy)-phenyll-morpholin-4-y1}-propionic acid hydrochloride Rt = 1.73 min.
Compound 50: 3-{214-(3-Fluoro-phenoxy)-phenyll-morpholin-4-y1}-propionic acid hydrochloride Rt = 1.63 min.
Compound 51: 3-{ 2-acid hydrochloride Rt = 1.60 min.
Compound 52: 3-{244-(Benzo[1,3]dioxo1-5-yloxy)-phenyThmorpholin-4-y1}-propionic acid hydrochloride Rt = 1.62 min.
Compound 53: 3-{244-(3-Fluoro-4-methyl-phenoxy)-phenyll-morpholin-4-yll-propionic acid hydrochloride Rt = 1.91 min.
Compound 54: 3-{244-(4-Methanesulfonyl-phenoxy)-phenyll-morpholin-4-yll-propionic acid hydrochloride Rt = 1.46 min.
Compound 55: 3-{ 2-acid hydrochloride Rt = 1.54 min.
Compound 56: 3-{ 2-acid hydrochloride Rt = 1.00 min.
Compound 57: 3-{214-(4-Benzyloxy-phenoxy)-phenyll-morpholin-4-yll-propionic acid hydrochloride Rt = 1.00 min.
Compound 58: 3-{214-(4-Trifluoromethoxy-phenoxy)-phenyll-morpholin-4-y1}-propionic acid hydrochloride Rt = 1.78 min.
Compound 59: 3-{214-(2-Trifluoromethoxy-phenoxy)-phenyll-morpholin-4-y1}-propionic acid hydrochloride Rt = 1.73 min.
Compound 60: 3-{ 2-acid hydrochloride Rt = 1.45 min.
Compound 61: 3-{214-(2-Fluoro-phenoxy)-phenyll-morpholin-4-y1}-propionic acid hydrochloride Rt = 1.63 mill.
Compound 62: 3-{ 2-acid hydrochloride Rt = 1.63 min.
Compound 63: 3-1214-(2,3-Dichloro-phenoxy)-phenyll-morpholin-4-y11-propionic acid hydrochloride Rt = 1.79 min.

Compound 64: 342-(4-p-Tolyloxy-phenyl)-morpholin-4-y11-propionic acid hydrochloride Rt = 1.66 min.
Compound 65: 3-{214-(3,4-Dichloro-phenoxy)-phenyll-morpholin-4-yll-propionic acid hydrochloride Rt = 1.77 min.
5 Compound 66: 3-{214-(3,5-Bis-trifluoromethyl-phenoxy)-phenyl]-morpholin-4-yll-propionic acid hydrochloride Rt = 1.96 min.
Compound 67: 3-{ 2-acid hydrochloride Rt = 1.82 min.
Compound 68: 3-{2-[4-(Naphthalen-2-yloxy)-phenyll-morpholin-4-yll-10 propionic acid hydrochloride Rt = 1.75 min.
Method C:
Compound 91: 3-{214-(2-Chloro-phenoxy)-phenyl]-1-oxo-thiomorpholin-4-yll-propionic acid trifluoroacetic acid salt: To a 15 .. solution of 3-{2-[4-(2-Chloro-phenoxy)-pheny1]-1-oxo-thiomorpholin-4-yll-pro-pionic acid tert-butyl ester (0.19 g; 0.42 mmol) in CH2C12 (10 mL) was added TFA (2 mL). The resulting mixture was stirred, at RT, overnight'treated with toluene, and concentrated in vacuo. The residue was dissolved in CH2C12 and concentrated in vacuo to afford 3-{244-(2-Chloro-phenoxy)-pheny1]-1-oxo-20 thiomorpholin-4-yll-propionic acid trifluoroacetic acid salt as an oil (0.17 g). 111 NMR (400 MHz, DMSO-d6) 0 ppm 2.83 (t, J = 8 Hz, 2 H), 2.92-3.13 (m, 1H), 3.21-3.34 (m, 2H), 3.34-3.44 (m, 2H), 3.44-3.61 (m, 2H), 3.86 (t, J = 12 Hz, 1H), 4.44 (d, J = 12 Hz, 1H), 7.04 (m, 2H), 7.23 (d, J = 8 Hz, 1H), 7.33 (m, 1H), 7.40 (dd, J = 8 and 2 Hz, 111), 7.47 (m, 2H), 7.69 (dd, J = 8 and 2 Hz, 1H), 11.00-25 13.00 (bs, 11-1).
The following compound was prepared according to a similar method:
Compound 92: 3-{ 2-acid trifluoroacetic acid salt: 11-1-NMR
30 (400 Mhz, DMSO-d6) 0 ppm 1.97 (s, 3H), 2.20 (s, 311), 2.75 (t, J = 8 Hz, 2H), 3.10-3.28 (m, 2H), 3.28-3.43 (m, 2H), 3.43-3.63 (m, 2H), 3.83 (t, J = 12 Hz, 1H), 4.33 (d, J = 12 Hz, 1H), 6.72 (d, J = 8 Hz, 1H), 6.80 (d, J = 8 Hz, 2H), 6.98 (d, J
= 8 Hz, 211), 7.06 (t, J = 8 Hz, 1H), 7.20 (d, J = 8 Hz, 2H), 10.00-12.50 (bs, 1H).
Table 1 R2 N ..õ.Thr,OH
R1,A 0 0 Comp. R1 A R2 R5 Method Ail CI
1 MP -õ NH H H A
CI
2 161-õ NH H H A
3 1101-,, C=0 H H A

C=0 H H A
F,C
C=0 H H A
ego,h CI
6 WP- õ, C=0 H H A
CI

F,C

Comp. R1 A R2 R5 Method 9 101,õ 0 H H A
ec& CI
IIP õ, 0 H H A
CI
11 S 0 H H B I õ, 12 F>LF SI 0 H H B
F

F
F
o'l 14 L,,,N 0 H H B

F
F
F

F
F
F tie, F
F

Comp. R1 A R2 R5 Method N

. = . , F
CI riah lir õ s 21 FO' 0 H H B
22 =N 401,õ 0 H H B
I

24 0 ,,, 0 H H B
I
N /
CI ti&h gr..,

26 0 H H B
a igihµ

27 F lir ._, 0 H H B
F
F

Comp. R1 A R2 R5 Method N

28 I ,t 0 H H B

29 õ_0 H H B
F
F

30 0 H H B
F
Fi0 Aki

31 0 H H B
F tup,õ

32 1 0 H H B
N
I

33 or ,, 0 H H B

34 0 111101, 0 H H B

F
F

35 0 F 0 H H B

36 0 H H B
11101 ,,, Comp. R1 A R2 R5 Method

37 0 --, 0 H H B

38 0 H H B
N,_,..5.--,,

39 F ri&I

40 Ss.. 0 H H B
F id.h. F

41 0 H H B

42 Aka 0,,

43 0 H H B
F

44 0 = . _ 0 H H B
F

45 0 0

46 0

47 101 = , , 0 H H B

Comp. R1 A R2 R5 Method F
F

48 F drk. 0 H H B

49 0 H H B

50 0 H H B

51 '.o It-. 0 H H B

52 <0 i,

53 0 H H B
F ISL-0õ ,0 s

54 .. Ali

55 0 H H B
1101õ,

56 ZIIJL 0 H H B

57 0 0 Ali 0 H H B
Ur .õ

Comp. R1 A R2 R5 Method F...1,0 do,i

58 F WI 0 H H B
F -õ
All (D\<,FF

59 0 H H B
I I
H

60 110 N.Ir

61 0 H H B
F

62 F0 0 H H B
CI
ei&,h CI

63 0 H H B

64 0 0 H H B
CI tish.

65 0 H H B
CI lir õ, F F F

66 0 H H B
F
F
CI

67 0 H H B

Comp. R1 A R2 R5 Method

68 SO -õ 0 H H B
Ak. a

69 lir õ, 0 3-C1 H A
CI
ec& CI

70 LIP- õ, 0 2-F H A
CI
Ak. a

71 lir õ, 0 2-CF3 H A
CI
tc& CI

72 1.1õ, 0 H 5,5-Me2 A
CI
a

73 00 H 2,2-Me2 A
a

74 -,, SO2 H H A
0 -,, SO2 H H A
a Ci

75 PCT/EP2011/061590 Comp. R1 A R2 R5 Method 78 0 õ 0 H 5-oxo A
=
ec& CI
79 LIP- õ, 0 H 2-Me A
CI
0 õ , 0 H 2-Me A
81 S. S H H A
CI

83 0 õ. S H H A
C) 1.1 0 NrOH

Table 2 (D' 0 0 N,R3 Comp. R3 Method 1r.OH
A

--,..OH

r0H

76 Table 3 wTh N .1, OH
R1,o 41) 0 Comp. R1 W Method 88 S. S A
CI
89 (101,,, S A
90 S. S A
CI
91 SI õ, SO C
CI
92 Os., SO C
93 0 ,õ SO2 A

77 5. PHARMACOLOGICAL TESTS & DATA
In vitro functional activity (agonism) on human S1P5 receptors The CHO-human-S1P5-Aegorin assay was bought from Euroscreen, Brussels (Euroscreen, Technical dossier, Human Lysophospholid S1P5 (Edg8) receptor, DNA clone and CHO AequoScreenTM recombinant cell-line, catalog n : ES-593-A, September 2006). Human-51P5-Aequorin cells express mitochondrial targeted apo-Aequorin. Cells have to be loaded with coelanterazine, in order to reconstitute active Aequorin. After binding of agonists to the human S1P5 .. receptor the intracellular calcium concentration increases and binding of calcium to the apo-Aequorin/coelenterazine complex leads to an oxidation reaction of coelenterazine, which results in the production of apo-Aequorin, coelenteramide, CO2 and light (0 max 469nm). This luminescent response is dependent on the agonist concentration. Luminescence is measured using the MicroBeta Jet (Perkin Elmer). Agonistic effects of compounds are expressed as pEC5o. Compounds were tested at a 10 points half log concentration range, and 3 independent experiments were performed in single point's measurements.
In vitro functional activity (agonism) on human S1P3 receptors The CHO-human-S1P3- Aeqorin assay (CHO/Ga16/AEQ/h-51P3) was established at Solvay Pharmaceuticals. The plasmid DNA coding for the S1P3 receptor (accession number in GenBank NM_005226 was purchased from UMR cDNA resource Centre (Rolla, MO). The pcDNA3.1/hS1P3 construct carrying the mitochondrially targeted apo-Aeqorin and Ga16 protein was transfected in CHO K1 cell-line.
Human-S1P3-Aequorin cells express mitochondrial targeted apo-Aequorin.
Cells have to be loaded with coelanterazine, in order to reconstitute active Aequorin. After binding of agonists to the human 51P3 receptor the intracellular calcium concentration increases and binding of calcium to the apo-Aequorin/coelenterazine complex leads to an oxidation reaction of

78 coelenterazine, which results in the production of apo-Aequorin, coelenteramide, CO2 and light (0 max 469nm). This luminescent response is dependent on the agonist concentration. Luminescence is measured using the MicroBeta Jet (Perkin Elmer). Agonistic effects of compounds are expressed as pEC50. Compounds were tested at a 10 points half log concentration range, and 3 independent experiments were performed in single point's measurements.
In vitro functional activity (agonism) on human S1P1 receptors The CHO-K1-Human S1P1-c-AMP assay was performed at Euroscreenfast, Brussels (Euroscreen, Human S1P1 coupling Gm (Edgl) receptor, catalog n :
FAST-0197C, December 2009).
Recombinant CHO-K1 cells expressing human S1P1, grown to mid-log Phase in culture media without antibiotics, detached, centrifuged and re-suspended.
For agonist testing cells are mixed with compound and Forskolin and incubated at room temperature. Cells are lyses and cAMP concentration are estimated, according to the manufacturer specification, With the HTRF kit from CIS-BIO International (cat n 62AM2PEB).
Agonistic effects of compounds are expressed as a percentage of the activity of the reference compound at its ECioo concentration, EC50 is calculated and results are reported as pEC5o. Compounds were tested at a 10 points half log concentration range duplicated in 1 experiment.
Pharmacological data (receptor agonism) for selected compounds:
Compound S1P5 S1P1 S1P3 pEC5o pEC5o pEC5o 2 6.2 nd <5.0 6 6.3 <5.5 <5.0 15 6.3 nd <5.0 26 5.7 nd 5.3

79 29 7.2 nd <5.0 35 6.7 nd <5.0 47 6.7 nd <5.0 57 5.7 nd <5.0 64 5.8 nd <5.0 68 6.2 nd <5.0 73 6.8 <5.5 nd

80 6.2 <4.5 <5.0 87 6.0 nd nd nd = not determined.
In vivo therapeutic model; T-maze Age-related memory deficits occur in humans and rodents. Spontaneous alternation is the innate tendency of rodents to alternate free choices in a T-maze over a series of successive runs. This sequential procedure relies on working memory and is sensitive to various pharmacological manipulations affecting memory processes (Aging and the physiology of spatial memory.
Barnes C.A. Neurobiol. Aging 1988:563-8; Dember WN, Fowler H.
Spontaneous alternation behavior. Psychol. Bull. 1958, 55(6):412-427; Gerlai R. A new continuous alternation task in T-maze detects hippocampal dysfunction in mice. A strain comparison and lesion study. Behav Brain Res 1998 95(1):91-101).
For this study, male C57BL/6J mice of 2 months or 12 months old may be used in the spontaneous alternation task in the T-maze. In short, mice are subjected to 1 session containing 15 trials, consisting of 1 "forced-choice" trial, followed by 14 "free-choice" trials. The animal is considered as entering one of the arms of the maze when all four paws are placed within this arm. A session is terminated and the animal is removed from the maze as soon as 14 free-choice trials have been performed or 15 min have elapsed, whatever event occurs first. The percentage of alternation over the 14 free-choice trials is determined for each mouse and is used as an index of working memory performance. A
compound of the invention may be administrated p.o. for 21 days prior the T-maze assay and on the day of the T-maze at t = -30 min. Compounds of the invention at doses ranging from of 0.01 ¨ 15 mg/kg/day may reverse the age-5 related cognitive decline in the 12-month old C57BL6J mice with up to 100%.
Thus, treated 12 month old mice may become identical in their performance as 2 months old vehicle-treated mice.

Claims

1. A bisaryl (thio)morpholine derivative of the formula (I) wherein R1 is an aryl substituent selected from phenyl, pyridyl, pyrimidinyl, biphenyl and naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-6C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, amino, di(1-4C)alkylamino, -SO 2-(1-4C)alkyl, -CO-(1-4C)alkyl, -CO-O-(1-4C)alkyl and -NH-CO-(1-4C)alkyl, or substituted with phenoxy, benzyl, benzyloxy, phenylethyl or morpholinyl, each optionally substituted with (1-4C)alkyl, or R1 is a (8-10C)bicyclic group or bicyclic heterocycle, each optionally substituted with (1-4C)alkyl optionally substituted with one or more fluoro atoms or oxo;
A is selected from -CO-, -NH-, -O-, -S-, -SO- or -SO 2-;
ring structure B optionally contains one nitrogen atom;
R2 is H, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is (1-4C)alkylene-R6 wherein the alkylene group may be substituted with (CH 2)2 to form a cyclopropyl moiety or with one or more halogen atoms, or R3 is (3-6C)cycloalkylene-R5 or -CO-CH 2-R6, wherein R6 is -OH, -PO 3H2, -OPO 3H2, -COOH, -COO(1-4C)alkyl or tetrazol-5-yl;
R4 is H or (1-4C)alkyl;
R5 is one or more substituents independently selected from H, (1-4C)alkyl or oxo;
W is -O-, -S-, -SO- or -SO 2-;
or a pharmaceutically acceptable salt, a solvate or hydrate thereof, with the proviso that the derivative of formula (I) is not 2- [4-(4-chlorophenoxy)-2-chloro-phenyl]-4-morpholineethanol.

2. The compound of claim 1, having the structure (II)

3. The compound of claim 1 or 2, wherein R3 is selected from -(CH 2)2-OH, -CH 2-COOH, -(CH 2)2-COOH, -(CH 2)3-COOH, -CH 2-CHCH 3-COOH, -CH 2-C(CH 3)2-COOH, -CHCH 3-CH 2-COOH, -CH 2-CF 2-COOH, -CO-CH 2-COOH, -(CH 2)2-PO 3H2, -(CH 2)3-PO 3H2, -(CH 2)2OPO 3H2, -(CH 2)3-OPO 3H2, -CH 2-tetrazol-5-yl, -(CH 2)2-tetrazol-5-yl and -(CH 2)3-tetrazol-5-yl;
and R4 is H.

4. The compound of claim 2, wherein R3 is -(CH 2)2-COOH.

5. The compound of any one of claims 1 - 4, wherein W is -O- or -S- and R2 is H or halogen.

6. The compound of any one of claims 1 - 5, wherein the ring structure B is phenylene.

7. The compound of any one of claims 1 - 6, wherein R5 is H.

8. The compound of any one of claims 1 to 7, wherein R1 is selected from pyridyl, pyrimidinyl, biphenyl, naphthyl, dihydrobenzofuranyl optionally substituted with oxo, benzdioxanyl, quinolinyl, isoquinolinyl and phenyl optionally substituted with one or more substituents independently selected from halogen, (1-6C)alkyl, di(1-4C)alkylamino, -SO 2-(1-4C)alkyl, -CO-(1-4C)alkyl, -CO-O-(1-4C)alkyl, -NH-CO-(1-4C)alkyl, difluoromethyl, trifluoromethyl, difluoromethoxy and trifluoromethoxy, or substituted with phenoxy, benzyl, benzyloxy, phenylethyl or morpholinyl.

9. The compound of any one of claims 1-8, wherein A is selected from -CO-, -NH- and -O-.

10. The compound of claim 1, selected from 3-{2-[4-(2,6-Dichloro-phenylamino)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2,6-Dimethyl-phenylamino)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2,6-Dimethyl-benzoyl)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(3-Trifluoromethyl-benzoyl)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2-Methyl-benzoyl)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2,6-Dichloro-benzoyl)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-(4-o-Tolyloxy-phenyl)-morpholin-4-yl]-propionic acid, 3-{2-[4-(3-Trifluoromethyl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2,6-Dimethyl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2,6-Dichloro-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[3-Chloro-4-(2,6-dichloro-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2,6-Dichloro-phenoxy)-2-fluoro-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2,6-Dichloro-phenoxy)-2-trifluoromethyl-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2,6-Dichloro-phenoxy)-phenyl]-5,5-dimethyl-morpholin-4-yl}-propionic acid, 3-{6-[4-(2,6-Dichloro-phenoxy)-phenyl]-2,2-dimethyl-morpholin-4-yl}-propionic acid, 3-[2-(4-Benzenesulfonyl-phenyl)-morpholin-4-yl]-propionic acidõ
3-{2-[4-(Toluene-2-sulfonyl)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2-Chloro-benzenesulfonyl)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2,6-Dichloro-benzenesulfonyl)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[3-(2,6-Dimethyl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-[2-(4-Phenoxy-phenyl)-morpholin-4-yl]-propionic acid 3-{2-[4-(3-Trifluoromethoxy-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(3-Fluoro-5-trifluoromethyl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(4-Morpholin-4-yl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(3-Chloro-4-methyl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2,5-Bis-trifluoromethyl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2,4,6-Trifluoro-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(Quinolin-3-yloxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2,3-Difluoro-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(4-Chloro-3-methyl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(3-Difluoromethoxy-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(3-Dimethylamino-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(1-Oxo-indan-5-yloxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(Isoquinolin-5-yloxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(4-Chloro-2-methyl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(4-Butyl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(4-Chloro-3-trifluoromethyl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(Pyrimidin-2-yloxy)-phenyl]-morpholin-4-yl}-propionic acid hydrochloride, 3-{2-[4-(Naphthalen-1-yloxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2-Fluoro-6-trifluoromethyl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(4-Difluoromethoxy-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(Pyridin-2-yloxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(Isoquinolin-4-yloxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{4-[4-(2-Carboxy-ethyl)-morpholin-2-yl]-phenoxyl}-benzoic acid methyl ester, 3-{2-[4-(2-Trifluoromethyl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-[2-(4-m-Tolyloxy-phenyl)-morpholin-4yl]-propionic acid, 3-{2-[4-(3,5-Dimethyl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(Pyridin-3-yloxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(4-Fluoro-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2,3-Dimethyl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2,4-Difluoro-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2,4-Dimethyl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2-Methoxy-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(3,5-Difluoro-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(1-Oxo-1,3-dihydro-isobenzofuran-5-yloxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(4-Methoxy-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(3,4-Dimethyl-phenoxy)-phenyl}-morpholin-4-yl}-propionic acid, 3-{2-[4-(4-Trifluoromethyl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2,5-Dimethyl-phenoxy)-phenyl}-morpholin-4-yl}-propionic acid, 3-{2-[4-(3-Fluoro-phenoxy)-phenyl}-morpholin-4-yl}-propionic acid, 3-{2-[4-(3-Methoxy-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(Benzo[1,3]dioxo1-5-yloxy)-phenyl}-morpholin-4-yl}-propionic acid, 3-{2-[4-(3-Fluoro-4-methyl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(4-Methanesulfonyl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(4-Acetyl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(Biphenyl-4-yloxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(4-Benzyloxy-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(4-Trifluoromethoxy-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2-Trifluoromethoxy-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2-Acetylamino-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2-Fluoro-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2,5-Difluoro-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2,3-Dichloro-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-[2-(4-p-Tolyloxy-phenyl)-morpholin-4-yl}-propionic acid, 3-{2-[4-(3,4-Dichloro-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(3,5-Bis-trifluoromethyl-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(3,5-Dichloro-phenoxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(Naphthalen-2-yloxy)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2,6-Dichloro-phenoxy)-phenyl]-2-methyl-morpholin-4-yl}-prop ion ic acid, 3-{2-[4-(2,3-Dimethyl-phenoxy)-phenyl]-2-methyl-morpholin-4-yl}-propionic acid, 3-{2-[4-(2-Chloro-phenoxy)-phenyl}-thiomorpholin-4-yl}-propionic acid, 3-{2-[4-(2,3-Dimethyl-phenoxy)-phenyl]-thiomorpholin-4-yl}-propionic acid, 3-{2-[4-(2-Chloro-6-methyl-phenoxy)-phenyl]-thiomorpholin-4-yl}-propionic acid, 3-{2-[4-(2-Chloro-phenoxy)-phenyl]-1-oxo-thiomorpholin-4-yl}-propionic acid, 3-{2-[4-(2,3-Dimethyl-phenoxy)-phenyl]-1-oxo-thiomorpholin-4-yl}-propionic acid, 3-{2-[4-(2,6-Dimethyl-phenylsulfanyl)-phenyl]-morpholin-4-yl}-propionic acid, 3-{2-[4-(2,3-Dichloro-phenylsulfanyl)-phenyl}-morpholin-4-yl}-propionic acid, 3-[2-(4-o-Tolylsulfanyl-phenyl)-morpholin-4-yl]-propionic acid, 3-{2- [4-(2,3-Dimethyl-phenoxy)-phenyl]-morpholin-4-yl}-butyric acid, 3-{2-[4-(2,3-Dimethyl-phenoxy)-phenyl]-morpholin-4-yl}-2-methyl-propionic acid, 4-{2- [4-(2,3-Dimethyl-phenoxy)-phenyl]-morpholin-4-yl}-butyric acid, 3-{2-[4-(2,3-Dimethyl-phenoxy)-phenyl]-1,1-dioxo-1.lambda.6-thiomorpholin-4-yl}-propionic acid, and 3-{2-[4-(2,6-Dimethyl-phenoxy)-phenyl]-5-oxo-morpholin-4-yl}-propionic acid, or a pharmaceutically acceptable salt, a solvate or hydrate thereof.

11. The compound of claim 1 of formula or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 of formula or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 of formula or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1 of formula or a pharmaceutically acceptable salt thereof.

15. The compound of any one of claims 1 to 14 for use in the treatment, alleviation or prevention of diseases and conditions in which any S1P receptor is involved or in which modulation of the endogenous S1P signalling system via any S1P receptor is involved.

16. The compound of claim 15, wherein the disease is a CNS disorder.

17. The compound of claim 16 wherein the CNS disorder is a neurodegenerative disorder, a cognitive disorder, Alzheimer's disease, dementia, Nieman's Pick disease, cognitive deficits in schizophrenia, obsessive-compulsive behavior, major depression, autism, multiple sclerosis or pain.

18. The compound of claim 17 wherein the cognitive disorder is age-related cognitive decline.

19. The compound of claim 17 wherein the dementia is vascular dementia.

20. A pharmaceutical composition comprising the compound of any one of claims 1 to 14 and at least one pharmaceutically acceptable auxiliary.

21. Use of the compound of any one of claims 1 to 14 for the manufacture of a medicament for the treatment, alleviation or prevention of diseases and conditions in which any S1P receptor is involved or in which modulation of the endogenous S1P
signaling system via any S1P receptor is involved.